{"add": {"doc": {"field": [{"@name": "docid", "#text": "BR-TU.19771"}, {"@name": "filename", "#text": "3189_SantosFilho_HiltonOliveirados_D.pdf"}, {"@name": "filetype", "#text": "PDF"}, {"@name": "text", "#text": "HILTON OLIVEIRA DOS SANTOS FILHO \n\n \n \n \n\nESTUDO CL\u00cdNICO FASE I DE CARBONATO DE \nLODENAFILA, UM NOVO TIPO DE INIBIDOR DE \n\nFOSFODIESTERASE 5 (PDE5), EM VOLUNT\u00c1RIOS \nSAUD\u00c1VEIS DO SEXO MASCULINO. \n\n \n \nA PHASE I CLINICAL TRIAL OF LODENAFIL CARBONATE, A \nNEW PHOSPHODIESTERASE TYPE 5 (PDE5) INHIBITOR, IN \n\nHEALTHY MALE VOLUNTEERS. \n\n \n \n \n \n \n\n \n \n \n \n \n \n \n\n \n \n \n\nCampinas \n2013 \n\n \n \n \n \n \n\n\n\n \n \n\n \n\n \n\n \n\n \n\n \n\n \n\n \n\n \n\n \n\n \n\n \n\n \n\n \n\n \n\n \n\n \n\n \n\n \n\n \n\n \n\n \n\n \n\n \n\n \n\n \n\n \n\n \n\nii \n\n\n\n \n\n \n \n \n\n \n \n \nUNIVERSIDADE ESTADUAL DE CAMPINAS \n\nFaculdade de Ci\u00eancias M\u00e9dicas \n \n \n \n\n \nHILTON OLIVEIRA DOS SANTOS FILHO \n\n \nESTUDO CL\u00cdNICO FASE I DE CARBONATO DE LODENAFILA, UM \nNOVO TIPO DE INIBIDOR DE  FOSFODIESTERASE 5 (PDE5), EM \n\nVOLUNT\u00c1RIOS SAUD\u00c1VEIS DO SEXO MASCULINO \n\n  \n \n\nOrientador (a) / Supervisor: Prof. Dr. Gilberto De Nucci \n\n \n\n \n\nA PHASE I CLINICAL TRIAL OF LODENAFIL CARBONATE, A NEW \nPHOSPHODIESTERASE TYPE 5 (PDE5) INHIBITOR, IN HEALTHY \n\nMALE VOLUNTEERS \n\n \n \n\n \nTese de Doutorado apresentada ao Programa de P\u00f3s-Gradua\u00e7\u00e3o em \n\nCl\u00ednica M\u00e9dica da Faculdade de Ci\u00eancias M\u00e9dicas da Universidade de Campinas \npara obten\u00e7\u00e3o de t\u00edtulo de Doutor em Cl\u00ednica M\u00e9dica, \u00e1rea de concentra\u00e7\u00e3o Cl\u00ednica \nM\u00e9dica. \n \n\nDoctoral Thesis presented to the Internal Medicine Posgraduate \nProgram of the Faculty of Medical Sciences, State University of Campinas, for \nobtainment of the Ph.D. degree in Internal Medicine/Medical Sciences, \nspecialization in Internal Medicine. \n\n \n \n\n \nESTE EXEMPLAR CORRESPONDE \u00c0 VERS\u00c3O FINAL DA \nTESE DEFENDIDA PELO ALUNO HILTON OLIVEIRA DOS \nSANTOS FILHO E ORIENTADO PELO PROF. DR. \nGILBERTO DE NUCCI. \n \n \nAssinatura do Orientador \n \n \n\n \n \n \n\n \nCampinas  \n\n2013 \n\n\n\n \n\niv \n\nFICHA CATALOGR\u00c1FICA ELABORADA POR \nMARISTELLA SOARES DOS SANTOS \u2013 CRB8/8402  \n\nBIBLIOTECA DA FACULDADE DE CI\u00caNCIAS M\u00c9DICAS  \nUNICAMP \n\n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n\n \n \n \n \nInforma\u00e7\u00f5es para Biblioteca Digital \n \nT\u00edtulo em ingl\u00eas: A phase I clinical trial of lodenafil carbonate, a new \nphosphodiesterase type 5 (PDE5) inhibitor, in healthy male volunteers. \nPalavras-chave em ingl\u00eas: \nErectile dysfunction \nPhosphodiesterase type 5 (PDE5) inhibitors \nPharmacokinetics \nSafety \n\u00c1rea de concentra\u00e7\u00e3o: Cl\u00ednica M\u00e9dica \nTitula\u00e7\u00e3o: Doutor em Cl\u00ednica M\u00e9dica \nBanca examinadora:  \nGilberto De Nucci [Orientador] \nUbirajara Ferreira \nSara Teresinha Olalla Saad \nManoel Odorico de Moares Filho \nRoberto Soares de Moura \nData da defesa: 13-05-2013 \nPrograma de P\u00f3s-Gradua\u00e7\u00e3o: Cl\u00ednica M\u00e9dica \n \n\n \n Santos Filho, Hilton Oliveira dos, 1956- \n S237e    Estudo cl\u00ednico fase I de carbonato de lodenafila, um \n\nnovo tipo de inibidor de  fosfodiesterase 5 (PDE5), em \nvolunt\u00e1rios saud\u00e1veis do sexo masculino / Hilton Oliveira \ndos Santos Filho. -- Campinas, SP : [s.n.], 2013. \n\n \n    Orientador : Gilberto De Nucci. \n    Tese (Doutorado) - Universidade Estadual de \n\nCampinas, Faculdade de Ci\u00eancias M\u00e9dicas.  \n \n    1. Disfun\u00e7\u00e3o er\u00e9til. 2. Inibidores da fosfodiesterase \n\ntipo 5. 3. Farmacocin\u00e9tica. 4. Seguran\u00e7a. I. De Nucci, \nGilberto, 1958-. II. Universidade Estadual de Campinas. \nFaculdade de Ci\u00eancias M\u00e9dicas. III. T\u00edtulo.  \n\n \n\n\n\n\n\n \n \n\nDEDICAT\u00d3RIA \n\n \n\n \n\n \n\n \n\n \n\n \n\nAos meus pais, Hilton e Dalva:  \n\nDe quem Deus me deu a honra de ser filho, respons\u00e1veis por minha \n\nforma\u00e7\u00e3o \u00e9tica e profissional, meus grandes exemplos  \n\nde vida.   Meu amor por voc\u00eas \u00e9 infinito e eterno. \n\n \n\nA minha esposa F\u00e1tima, meus filhos Carla e Bruno:  \n\nRaz\u00f5es de minha vida, e a quem devo muito do que consegui at\u00e9 o momento. \n\nMeu amor incondicional e gratid\u00e3o. \n\n \n\nvi \n\n \n\n\n\n \n \n\nAGRADECIMENTOS \n\n \n\n \n\n \n\n \n\n \n\n \n\n \n\nAgrade\u00e7o a minha esposa, F\u00e1tima, pela enorme paci\u00eancia, amor incondicional e companheirismo. \n\nAos meus pais, Hilton e Dalva, pelo apoio em todos os meus projetos, por mais ousados que tenham \n\nsido. Sempre me estimularam a ir mais adiante e a acreditaram em meu potencial.  \n\nEm especial ao orientador Prof. Dr. Gilberto De Nucci pela confian\u00e7a; amizade, oportunidade de \n\naprendizado que tive a honra de receber.  Sua experi\u00eancia e seu conhecimento ser\u00e3o reconhecidos \n\neternamente por toda a comunidade acad\u00eamica nacional e internacional.  \n\n\u00c9 uma honra imensa poder ter este grande cientista e pessoa excepcional como meu orientador. \n\nEm especial ao Dr. M\u00e1rcio Falci, pela grande amizade, confian\u00e7a,  \n\naprendizado profissional e de vida durante v\u00e1rios anos. \n\nAgrade\u00e7o a todos que direta ou indiretamente contribu\u00edram para a realiza\u00e7\u00e3o desse trabalho. \n\nEspecialmente, aos que participam ou participaram dos grupos de pesquisa do  \n\nProf. Dr. Gilberto De Nucci. \n\nA TODOS, O MEU MAIS SINCERO MUITO OBRIGADO! \n\n \n\nvii \n\n\n\n \n \n\nCarbonato de Lodenafila \u00e9 um novo tipo de inibidor de fosfodiesterase 5 (PDE5) utilizado no \n\ntratamento da disfun\u00e7\u00e3o er\u00e9til. O presente estudo foi realizado para avaliar a seguran\u00e7a, \n\ntolerabilidade e farmacocin\u00e9tica do carbonato de lodenafila ap\u00f3s a administra\u00e7\u00e3o de doses \n\norais \u00fanicas ascendentes (de 1 a 100 mg) a volunt\u00e1rios saud\u00e1veis do sexo masculino (n = 33). \n\nO estudo foi um estudo cl\u00ednico fase I, aberto, de escalonamento de dose, utilizando a \n\nadministra\u00e7\u00e3o de doses orais \u00fanicas de carbonato de lodenafila. Carbonato de Lodenafila foi \n\nadministrado sequencialmente escalonado em doses \u00fanicas de 1 mg a 100 mg com um \n\nper\u00edodo sem uso do medicamento (washout) de pelo menos 1 semana, entre cada dose. A \n\nprogress\u00e3o para a pr\u00f3xima dose foi permitida se ap\u00f3s a avalia\u00e7\u00e3o dos exames cl\u00ednicos, \n\nlaboratoriais e Monitoriza\u00e7\u00e3o Ambulatorial da Press\u00e3o Arterial (MAPA), n\u00e3o demonstrassem \n\naltera\u00e7\u00f5es e eventos adversos sem relev\u00e2ncia cl\u00ednica. As amostras de sangue foram coletadas \n\nna pr\u00e9-dose e em intervalos determinados e 24 horas ap\u00f3s a administra\u00e7\u00e3o. As amostras de \n\nplasma para a mensura\u00e7\u00e3o de carbonato lodenafila e lodenafila foram analisadas por \n\ncromatografia l\u00edquida acoplada \u00e0 espectrometria de massa. N\u00e3o foram observados eventos \n\nadversos graves, e nenhum dos volunt\u00e1rios abandonou o estudo devido \u00e0 intoler\u00e2ncia. As \n\nmedi\u00e7\u00f5es do MAPA, exames cl\u00ednicos e laboratoriais e ECG n\u00e3o revelaram altera\u00e7\u00f5es \n\nsignificativas mesmo em doses mais elevadas. Carbonato Lodenafila n\u00e3o foi detectado em \n\nqualquer amostra, indicando que ele atua como um pr\u00f3-droga. Os par\u00e2metros \n\nfarmacocin\u00e9ticos m\u00e9dios de lodenafila para tmax e t1 / 2 foram 1,6 (\u00b1 0,4) horas e 3,3 (\u00b1 1,1) \n\nhoras, respectivamente. Este estudo demonstrou que o carbonato de lodenafila \u00e9 bem tolerado \n\ne apresentou um bom perfil de seguran\u00e7a em volunt\u00e1rios saud\u00e1veis do sexo masculino. \n\n Palavras-chave: inibidores da fosfodiesterase tipo 5 (PDE5), farmacocin\u00e9tica, seguran\u00e7a. \n\nResumo \n\nviii \n\n\n\n \n \n\nLodenafil carbonate is a new phosphodiesterase type 5 (PDE5) inhibitor used in treatment of \n\nerectile dysfunction. The present study was conducted to evaluate the safety, tolerability, and \n\npharmacokinetics of lodenafil carbonate after administering ascending (1 to 100 mg) single \n\noral doses to healthy male volunteers (n=33). The study was an open-label, dose-escalation, \n\nphase I clinical trial involving the administration of single oral doses of lodenafil carbonate. \n\nLodenafil carbonate was administered sequentially, escalating in single doses of 1 mg to 100 \n\nmg with a washout period of at least 1 week between each dose. The progression to the next \n\ndose was allowed after clinical and laboratory exams, Ambulatory Monitoring of Arterial \n\nPressure (AMAP) without relevant clinical modifications and adverse events without clinical \n\nrelevancy. Blood samples were collected at pre-dose, determined intervals and 24h post-\n\ndosing. Plasma samples for measurement of lodenafil carbonate and lodenafil were analyzed \n\nby liquid chromatography coupled to tandem mass spectrometry. No serious adverse events \n\nwere observed, and none of the subjects discontinued the study due to intolerance. The \n\nAMAP measurements, clinical and laboratory exams and ECG revealed no significant \n\nchanges even at higher doses. Lodenafil carbonate was not detected in any samples, indicating \n\nthat it acts as a pro-drug. The mean lodenafil pharmacokinetic parameters for tmax and t1/2 \n\nwere 1.6 (\u00b10.4) hr and 3.3 (\u00b11.1) hr, respectively. This study demonstrated that lodenafil \n\ncarbonate was well tolerated and showed a good safety profile in healthy male volunteers. \n\nKey words: phosphodiesterase type 5 (PDE5) inhibitor, pharmacokinetics, safety \n\n \n\n \n\nAbstract \n\nix \n\n \n\n\n\n \n \n\nLista de abreviaturas \n\nAMPc: Monofosfato c\u00edclico de adenosina \n\nANVISA: Ag\u00eancia Nacional de Vigil\u00e2ncia Sanit\u00e1ria \n\nAVC: Acidente vascular cerebral  \n\nBNDES: Banco Nacional do Desenvolvimento Econ\u00f4mico e Social \n\nCEMIB: Centro Multidisciplinar para Investiga\u00e7\u00e3o Biol\u00f3gica na \u00c1rea da Ci\u00eancia em Animais \nde Laborat\u00f3rio \n\nCTC: Common toxicity criteria - crit\u00e9rio comum de toxicidade \n\nDE: Disfun\u00e7\u00e3o er\u00e9til  \n\nDL50: dose letal 50% \n\nDLT: dose-limiting toxicity - dose limite de toxicidade  \n\nEC50: Efeito m\u00e1ximo 50% - concentra\u00e7\u00e3o de droga necess\u00e1ria para produzir 50% do efeito \nm\u00e1ximo \n\nFINEP: Financiadora de Estudos e Projetos \n\nFOB: Functional observation battery - bateria de observa\u00e7\u00e3o funcional \n\nGMPc: Monofosfato c\u00edclico de guanosina \n\nHED: Human equivalent dose - dose equivalente humana \n\nIIEF: International Index for Erectile Function- \u00cdndice internacional de Fun\u00e7\u00e3o Er\u00e9til \n\nIIEF5: \u00cdndice Internacional de Fun\u00e7\u00e3o Er\u00e9til-5  \n\nMAPA: Monitoriza\u00e7\u00e3o ambulatorial da press\u00e3o arterial  \n\nMRSD: Maximum recommended starting dose - dose m\u00e1xima inicial \n\nMTD: Maximum tolerable dosage - dose m\u00e1xima tolerada \n\nNOAEL: No observed adverse effect level \u2013 n\u00edvel de efeito adverso n\u00e3o observado \n\nP&amp;D: Pesquisa e Desenvolvimento  \n\nPDE5: inibidores da fosfodiesterase tipo 5  \n\npEC50: antilog da concentra\u00e7\u00e3o de droga necess\u00e1ria para produzir 50% do efeito m\u00e1ximo \n\nTRPN: Tumesc\u00eancia e rigidez peniana noturna  \n\nUNICAMP: Universidade Estadual de Campinas \n\n \n\n \n\nx \n\n\n\n \n \n\nLista de tabelas \n\nTable 1: Treatment scheme with lodenafil in 1 mg, 2 mg, 3 mg, 5 mg, 8 mg, \n\n10 mg, 20 mg, 30 g, 50 mg, 80 mg and 100 mg in healthy male \n\nvolunteers\u2026\u2026\u2026\u2026\u2026\u2026\u2026\u2026\u2026\u2026\u2026\u2026\u2026\u2026\u2026\u2026\u2026\u2026\u2026\u2026\u2026\u2026\u2026\u2026\u2026\u2026\u2026 \n\n \n \n \n \n \n\n46 \n\nTable 2: Accuracy and precision data for lodenafil carbonate and lodenafil \n\nfrom the pre-study validation in human \n\nplasma\u2026\u2026\u2026\u2026\u2026\u2026\u2026\u2026\u2026\u2026\u2026\u2026\u2026\u2026................................................ \n\n \n \n \n \n \n\n47 \n\nTable 3: Mean pharmacokinetic parameters obtained from volunteers after \n\nadministration of lodenafil carbonate formulation (1 mg, 2 mg, 3 mg, 5 mg, 8 \n\nmg, 10 mg, 20 mg, 30 mg, 50 mg, 80 mg and 100 mg) in 33 healthy \n\nvolunteers\u2026\u2026\u2026\u2026\u2026\u2026\u2026\u2026\u2026\u2026\u2026\u2026\u2026\u2026\u2026\u2026\u2026\u2026\u2026\u2026\u2026\u2026\u2026\u2026\u2026\u2026\u2026 \n\nTable 4: Laboratory tests in healthy male volunteers after administration of \nlodenafil carbonate\u2026\u2026\u2026\u2026\u2026\u2026\u2026\u2026\u2026\u2026\u2026\u2026\u2026\u2026\u2026\u2026\u2026\u2026\u2026\u2026\u2026\u2026\u2026 \n \n\n \n \n \n \n \n \n \n \n\n48 \n \n \n \n\n49 \n \n\nTable 5: Mean sitting systolic and diastolic blood pressures and mean heart \n\nrates after lodenafil carbonate administration \u2026\u2026\u2026\u2026\u2026\u2026\u2026\u2026\u2026\u2026\u2026\u2026 \n\n \n \n\n \n50 \n\n \n\n \n\n \n\n \n\n \n\n \n\nxi \n\n \n\n\n\n \n \n\nLista de figuras \n\n \n\nFigure 1: The mean lodenafil plasma concentrations vs. time profiles after a \nsingle oral dose (1 mg, 2 mg, 3 mg, 5 mg, 8 mg, 10 mg, 20 mg, 30 mg, 50 mg, \n80 mg, 100 mg) tablet formulation of lodenafil carbonate in male volunteers... \n\n \n \n51 \n\n \nFigure 2: Mean sitting systolic and diastolic blood pressures and sitting heart \nrates after lodenafil carbonate administration\u2026\u2026\u2026\u2026\u2026\u2026\u2026\u2026\u2026\u2026\u2026\u2026\u2026.. \n\n \n \n52 \n\n \n\n \n\n \n\n \n\n \n\n \n\n \n\n \n\n \n\n \n\n \n\n \n\n \n\nxii \n\n \n\n \n\n\n\n \n \n\n \n\nSUM\u00c1RIO \n\nResumo................................................................................................................. viii \nAbstract................................................................................................................. ix \nLista de abreviaturas............................................................................................. x \nLista de tabelas..................................................................................................... xi \nLista de figuras...................................................................................................... xii \n1. Introdu\u00e7\u00e3o geral............................................................................................... 14 \n     1.1 Fisiologia e fisiopatologia da disfun\u00e7\u00e3o er\u00e9til......................................... 16 \n     1.2 Diagn\u00f3stico da disfun\u00e7\u00e3o er\u00e9til.................................................................. 17 \n     1.3 Tratamento da disfun\u00e7\u00e3o er\u00e9til.................................................................. 19 \n     1.3.1. Tratamento de primeira linha................................................................ 19 \n     1.3.2. Tratamento de segunda linha............................................................... 21 \n     1.3.3 Tratamento de terceira linha (pr\u00f3tese peniana) .................................... 21 \n     1.4 O desenvolvimento de um novo medicamento......................................... 22 \n     1.4.1 Estudos Cl\u00ednicos: fase I, II, III e IV....................................................... 24 \n     1.5 Estudos preliminares com o carbonato de lodenafila................................ 27 \n     1.5.1 Estudos pr\u00e9-cl\u00ednicos de toxicidade.......................................................... 29 \n     1.6 Objetivo. ................................................................................................... 30 \n2. Cap\u00edtulo I........................................................................................................... 31 \n3. Discuss\u00e3o.......................................................................................................... 53 \n4. Conclus\u00e3o.......................................................................................................... 55 \n5. Refer\u00eancias bibliogr\u00e1ficas................................................................................. 56 \nAnexos................................................................................................................... 59 \n\n \n\n \n\n \n\n \n\n \n\n \n\n \n\n\n\n \n\n14 \n \n\n1. Introdu\u00e7\u00e3o Geral \n\n \n\nA disfun\u00e7\u00e3o er\u00e9til (DE) \u00e9 uma condi\u00e7\u00e3o cl\u00ednica definida como a incapacidade \n\npersistente de obter ou manter uma ere\u00e7\u00e3o suficiente para permitir um desempenho sexual \n\nsatisfat\u00f3rio (1, 2). \n\n\u00c9 considerada por muitos como uma doen\u00e7a, tendo em vista seu amplo espectro de dano \n\nao indiv\u00edduo. Apesar de benigna, acomete o indiv\u00edduo e seus familiares tendo em vista que \n\ntanto a sa\u00fade f\u00edsica como a psicossocial se encontram afetada (3). \n\nEm rela\u00e7\u00e3o \u00e0 sua epidemiologia, a literatura demonstra dados de incid\u00eancia e \n\npreval\u00eancia com varia\u00e7\u00f5es amplas. Este fato deve-se provavelmente a diversos fatores, como \n\ndiferentes metodologias utilizadas, idade e condi\u00e7\u00e3o socioecon\u00f4mica das popula\u00e7\u00f5es \n\nestudadas.  \n\nNo entanto, uma revis\u00e3o dos estudos epidemiol\u00f3gicos, realizada em 2003, sugere que a \n\nDE de intensidade moderada a severa, afeta 5% a 20% dos homens (4). \n\nEstudo realizado na popula\u00e7\u00e3o brasileira demonstrou que 25 milh\u00f5es de homens com \n\nmais de 18 anos apresentam algum grau de DE e aproximadamente 11 milh\u00f5es tenham \n\ndisfun\u00e7\u00e3o er\u00e9til moderada ou severa. A incid\u00eancia de DE na popula\u00e7\u00e3o brasileira foi de 65,6 \n\ncasos por 1.000 pessoas /ano. Com a proje\u00e7\u00e3o de um milh\u00e3o de novos casos anualmente \n\ndemonstra que a DE deve ser considerada um problema de sa\u00fade p\u00fablica (5,6).  \n\nComo ser\u00e1 abordado em maiores detalhes a seguir, o desenvolvimento de um novo \n\nf\u00e1rmaco \u00e9 extremamente complexo e com taxa de sucesso baixa, mesmo em pa\u00edses onde este \n\nprocedimento j\u00e1 \u00e9 muito bem conhecido e executado. \n\n\n\n \n\n15 \n \n\nO medicamento abordado neste trabalho foi desenvolvido, patenteado e registrado na \n\nAg\u00eancia Nacional de Vigil\u00e2ncia Sanit\u00e1ria (ANVISA) para comercializa\u00e7\u00e3o, integralmente no \n\nBrasil, processo pioneiro em nosso pa\u00eds.  \n\nA denominada inova\u00e7\u00e3o colaborativa foi utilizada com muita propriedade durante todo \n\no processo de desenvolvimento. A integra\u00e7\u00e3o entre a universidade, ind\u00fastria e \u00f3rg\u00e3os \n\ngovernamentais, foi determinante para que o projeto fosse executado e o resultado esperado, \n\nalcan\u00e7ado. Um medicamento inovador com desenvolvimento inteiramente brasileiro. \n\nPodemos afirmar, sem receio de cometermos excessos, que a universidade, ind\u00fastria, \n\ngoverno e principalmente a popula\u00e7\u00e3o brasileira podem se orgulhar deste projeto, exemplo a \n\nser seguido por todos os setores envolvidos na pesquisa e desenvolvimento (P&amp;D) brasileiro.  \n\n \n\n\n\n \n\n 16  \n \n\n1.1 Fisiologia e fisiopatologia da Disfun\u00e7\u00e3o Er\u00e9til  \n\nA ere\u00e7\u00e3o \u00e9 resultado de uma complexa integra\u00e7\u00e3o de fun\u00e7\u00f5es neurais, hormonais e \n\nvasculares.  \n\nResumidamente, uma ere\u00e7\u00e3o ocorre quando o fluxo de sangue para o p\u00eanis excede o \n\nfluxo para fora do p\u00eanis, conforme detalhado a seguir.  \n\nAs art\u00e9rias cavernosas fornecem sangue para o corpo cavernoso do p\u00eanis (atrav\u00e9s da \n\nart\u00e9ria pudenda), enquanto as veias emiss\u00e1rias  drenam o corpo cavernoso (para a veia \n\npudenda interna). Durante a ere\u00e7\u00e3o, as fibras da musculatura lisa  do corpo cavernoso se \n\nencontram relaxadas, diminuindo a resist\u00eancia ao fluxo arterial para o corpo cavernoso e  \n\nconsequente  expans\u00e3o dos sinusoides nele contidos.  Esta distens\u00e3o causa compress\u00e3o \n\nmec\u00e2nica sobre as veias emiss\u00e1rias , o que impede a sua capacidade para drenar o sangue \n\nresultando em rigidez peniana. Durante a ere\u00e7\u00e3o, o p\u00eanis atua como um capacitor, \n\nacumulando sangue sob press\u00e3o devido ao relaxamento dos corpos cavernosos (7). \n\nO fluxo sangu\u00edneo do p\u00eanis \u00e9 controlado pelo centro da ere\u00e7\u00e3o auton\u00f4mica, atrav\u00e9s dos \n\nnervos parassimp\u00e1ticos (S2-S4), simp\u00e1ticos (T12-L2) e plexo p\u00e9lvico incluindo o nervo \n\ncavernoso, que inerva as art\u00e9rias e musculatura lisa trabecular do corpo cavernoso.   \n\nApesar de existir uma grande sinergia entre eles, dois mecanismos podem desencadear \n\nas altera\u00e7\u00f5es vasculares envolvidas na ere\u00e7\u00e3o peniana: psicog\u00eanicas e reflexog\u00eanicas.  \n\nAs psicog\u00eanicas agem atrav\u00e9s de est\u00edmulos como, som, odor, vis\u00e3o e tato. As \n\nreflexog\u00eanicas atrav\u00e9s da estimula\u00e7\u00e3o peniana direta.  \n\nNos dois mecanismos neurotransmissores s\u00e3o envolvidos na ere\u00e7\u00e3o e detumesc\u00eancia, \n\nentre eles a dopamina e noradrenalina. \n\n\n\n \n\n 17  \n \n\nOs horm\u00f4nios androg\u00eanicos atuam modulando a libido e comportamento sexual. A \n\ntestosterona aumenta o interesse e a frequ\u00eancia dos atos sexuais, no entanto n\u00e3o afeta as \n\nere\u00e7\u00f5es reflexog\u00eanicas e psicog\u00eanicos.   \n\nO neurotransmissor \u00f3xido n\u00edtrico, um dos mais importantes sinalizadores intra e \n\nextracelular \u00e9, em \u00faltima an\u00e1lise, o respons\u00e1vel pelo mecanismo de ere\u00e7\u00e3o e relaxamento \n\npeniano. \n\nEste sinalizador se difunde atrav\u00e9s da membrana do m\u00fasculo liso e ativa a guanilato \n\nciclase para produzir o monofosfato c\u00edclico de guanosina (GMPc) que desencadeia uma \n\ncascata de rea\u00e7\u00f5es bioqu\u00edmicas levando a uma altera\u00e7\u00e3o da permeabilidade dos canais i\u00f4nicos \n\nde c\u00e1lcio e pot\u00e1ssio. Esta altera\u00e7\u00e3o diminui o c\u00e1lcio intracelular promovendo o relaxamento \n\ndo m\u00fasculo liso, aumento do fluxo sangu\u00edneo e consequentemente ere\u00e7\u00e3o peniana. \n\nAs enzimas fosfodiesterases, principalmente a isoforma 5 (PDE5), regulam o \n\nmecanismo descrito acima catalisando a rea\u00e7\u00e3o inversa das guanilato ciclases e inativando o \n\nGMPc atrav\u00e9s da sua transforma\u00e7\u00e3o em GMP (8). \n\nPelo menos 11 fam\u00edlias de PDEs foram descritas em mam\u00edferos, mas como alguns tipos \n\nest\u00e3o associados a mais de um gene e podem diferir quanto \u00e0 afinidade e especificidade pelos \n\nposs\u00edveis substratos (GMPc ou AMPc), o resultado \u00e9 pelo menos 50 isotipos de PDEs. A \n\nPDE5 \u00e9 a fosfodiesterase predominante no corpo cavernoso do homem (9,10). \n\n \n\n1.2 Diagn\u00f3stico da Disfun\u00e7\u00e3o Er\u00e9til  \n\nConforme j\u00e1 descrito, a  ere\u00e7\u00e3o \u00e9 um fen\u00f4meno neurovascular sob controle hormonal.  \n\nA DE compartilha fatores de risco com as doen\u00e7a cardiovascular como  sedentarismo, \n\nobesidade, tabagismo, hipercolesterolemia e  s\u00edndrome metab\u00f3lica. Este fato \u00e9 importante pois \n\no conhecimento destes fatores de risco tem  impacto importante no tratamento da DE (11, 12).  \n\n\n\n \n\n 18  \n \n\nA etiologia da DE \u00e9 dividada em: vasculog\u00eanica, neurog\u00eanica, hormonal, anat\u00f4mica, \n\nmedicamentosa, ou psicog\u00eanica. \u00c9 comum mais de uma etiologia estar presente em um \n\nmesmo paciente. Por este motivo, a classifica\u00e7\u00e3o que inclui o termo mista, se aproxima muito \n\nda realidade cl\u00ednica da doen\u00e7a.  \n\nAs vasculog\u00eanicas est\u00e3o relacionadas \u00e0s doen\u00e7as cardiovasculares, hipertens\u00e3o, \n\ndiabetes mellitus, hiperlipidemia, tabagismo, cirurgias de grande porte ou radioterapia (p\u00e9lvis \n\nou retroperit\u00f4nio). \n\nAs neurog\u00eanicas s\u00e3o subdivididas em: causas centrais: como por exemplo, a esclerose \n\nm\u00faltipla; atrofia m\u00faltipla; doen\u00e7a de Parkinson; tumores; acidente vascular cerebral (AVC), \n\ndoen\u00e7as discais; causas perif\u00e9ricas: como por exemplo: diabetes mellitus; alcoolismo; \n\nuremia, olineuropatia e cir\u00fargicas (p\u00e9lvica, retroperit\u00f4nio, prostatectomia radical); causas \n\nanat\u00f4micas ou estruturais: doen\u00e7a de Peyronie; fratura peniana; curvatura cong\u00eanita do \n\np\u00eanis; microp\u00eanis; hiposp\u00e1dias, episp\u00e1dias. \n\nHormonal: hipogonadismo; hiperprolactinemia, hiper e hipotireoidismo e doen\u00e7a de \n\nCushing. \n\nMedicamentosa ou induzida por drogas: anti-hipertensivos (diur\u00e9ticos e \n\nbetabloqueadores), antidepressivos, antipsic\u00f3ticos, antiandrog\u00eanicos, anti-histam\u00ednicos e \n\ndrogas recreacionais (hero\u00edna, coca\u00edna, metadona). \n\nPsicog\u00eanica: tipo generalizado: falta de excitabilidade e disfun\u00e7\u00f5es na intimidade \n\nsexual, tipo situacional: relacionamento com parceira, problemas relacionados ao desempenho \n\nsexual.  \n\nO diagn\u00f3stico \u00e9 eminentemente cl\u00ednico, realizado ap\u00f3s anamnese detalhada e exame \n\ncl\u00ednico. Exames complementares podem auxiliar no diagn\u00f3stico, tais como, medida s\u00e9rica da \n\ntestosterona, glicemia de jejum e perfil lip\u00eddico, Ultrassonografia Doppler colorida com \n\n\n\n \n\n 19  \n \n\nere\u00e7\u00e3o f\u00e1rmaco induzida pr\u00e9via, tumesc\u00eancia e rigidez peniana noturna (TRPN) utilizando \n\nRigiscan (3, 13). Atualmente utiliza-se como ferramenta, tanto no diagn\u00f3stico como para \n\navalia\u00e7\u00e3o em estudos cl\u00ednicos o International Index for Erectile Function (IIEF), validada para \n\no portugu\u00eas como \u00cdndice Internacional de Fun\u00e7\u00e3o Er\u00e9til-5 (IIFE-5) (14). \n\n \n\n1.3 Tratamento da disfun\u00e7\u00e3o er\u00e9til  \n\n O tratamento, como na maioria das doen\u00e7as, deve seguir o principio de ser \n\nindividualizado e escalonado do menos invasivo e mais tolerado ao mais invasivo e menos \n\ntolerado. \n\nA orienta\u00e7\u00e3o do homem e do casal sobre sua sexualidade \u00e9 um ponto fundamental no \n\ntratamento da DE independente da etiologia. \n\n A psicoterapia e tratamento com psicof\u00e1rmacos t\u00eam apresentado bons resultados, tendo \n\nem vista que, principalmente em pacientes jovens, a etiologia mais frequente \u00e9 a psicog\u00eanica \n\n(15). \n\nDoen\u00e7as concomitantes e principalmente as cardiovasculares que compartilham dos \n\nmesmos fatores de risco, devem ser devidamente tratadas. \n\nEstudo demonstrou que se os fatores de risco para doen\u00e7as cardiovasculares forem \n\nmanejados adequadamente, al\u00e9m do risco card\u00edaco diminuir a DE pode ser controlada (12). \n\n \n\n1.3.1 Tratamento de primeira linha \n\nOs inibidores da Fosfodiesterase 5 (PDE5) s\u00e3o considerados o tratamento de primeira \n\nlinha para quase todas as etiologias. \n\n\n\n \n\n 20  \n \n\nA escolha do inibidor da PDE5 deve ser adequada \u00e0 expectativa do paciente. Estes \n\ndevem ser adequadamente informados quanto \u00e0s vantagens e poss\u00edveis desvantagens em seu \n\nuso. \n\nComo existem inibidores da PDE5 com meia vida variada comercializados no Brasil, \u00e9 \n\nimportante adaptar o tratamento aos h\u00e1bitos sexuais do paciente, frequ\u00eancia de rela\u00e7\u00f5es \n\nsexuais e a previsibilidade destas.  \n\nO primeiro inibidor da PDE5, sildenafila (Viagra \u00ae), introduzido no mercado em 1998, \n\nera utilizado de acordo com a necessidade (sob demanda) por suas caracter\u00edsticas \n\nfarmacol\u00f3gicas, principalmente a meia vida curta. Em 2008 a tadalafila (Cialis\u00ae) foi \n\naprovada para uso di\u00e1rio continuo, facilitando pacientes que tenha atividade sexual mais \n\nfrequente ou n\u00e3o previs\u00edvel (3). \n\nS\u00e3o comercializados no Brasil, al\u00e9m dos j\u00e1 descritos, Vardenafila (Levitra\u00ae, Vivanza\u00ae) \n\ne Lodenafila (Helleva\u00ae). \n\nOutros inibidores da PDE5 se encontram registrados ou em fase de registro em outros \n\npa\u00edses, como: Udenafila (Coreia e R\u00fassia, pendente FDA), Avanafila (em avalia\u00e7\u00e3o FDA), \n\nMirodenafila (Coreia), SLX-2101(fase II finalizado e em avalia\u00e7\u00e3o FDA) (16, 17).  \n\nOs inibidores da PDE5 registrados no Brasil s\u00e3o medicamentos com perfil de seguran\u00e7a \n\nadequados com os eventos adversos e contra indica\u00e7\u00f5es, formais e relativas, bem \n\nestabelecidas. \n\nPor serem vasodilatadores os eventos adversos mais comuns se relacionam a esta a\u00e7\u00e3o, \n\ncomo cefaleia, vermelhid\u00e3o, tontura e congest\u00e3o nasal. As menos frequentes s\u00e3o \n\nanormalidades visuais, dor nas costas /mialgias, taquicardia, hipotens\u00e3o, entre outros. \n\nInfartos do mioc\u00e1rdio n\u00e3o aumentaram ap\u00f3s o uso de PDE5 em diversos estudos (18). \n\nHipotens\u00e3o ortost\u00e1tica \u00e9 descrita com o uso concomitante a alfa-bloqueadores e finalmente, a \n\n\n\n \n\n 21  \n \n\ncontra indica\u00e7\u00e3o formal do uso com nitratos, por seus efeitos hipotensores imprevis\u00edveis, \n\npodendo levar a baixa perfus\u00e3o coronariana ao mioc\u00e1rdio.  \n\nDoses menores de inibidores de PDE5 podem ser necess\u00e1rias quando os pacientes \n\nestiverem recebendo cetoconazol, itraconazol, eritromicina, claritromicina e inibidores da \n\nprotease do HIV (ritonavir, saquinavir). Doses maiores de inibidores de PDE5 podem vir a ser \n\nnecess\u00e1rias em pacientes que est\u00e3o recebendo rifampicina, fenobarbital, fenito\u00edna ou \n\ncarbamazepina. A presen\u00e7a de insufici\u00eancia renal ou hep\u00e1tica pode levar \u00e0 necessidade de \n\najuste da dose dos inibidores de PDE. \n\nAntes de se iniciar um tratamento de segunda ou terceira linha recomenda-se a \n\nreposi\u00e7\u00e3o de testosterona, o que restabelece a efic\u00e1cia em pacientes hipogon\u00e1dicos n\u00e3o \n\nrespondedores aos inibidores de PDE5, observadas todas as contra indica\u00e7\u00f5es formais e \n\nrelativas desta reposi\u00e7\u00e3o. \n\n \n\n1.3.2 Tratamentos de segunda linha \n\nPacientes que n\u00e3o respondem adequadamente ao tratamento por via oral podem se \n\nbeneficiar com o uso de medicamentos injet\u00e1veis no corpo cavernoso, como o alprostadil e a \n\nassocia\u00e7\u00e3o de medicamentos alprostadil + papaverina + fentolamina, menos indicada por seus \n\nmaiores efeitos adversos, relacionados \u00e0 papaverina, principalmente a fibrose. \n\nAinda pode-se utilizar a prostaglandina E1 administrada por via intrauretral. \n\n \n\n1.3.3 Tratamento de terceira linha (pr\u00f3tese peniana) \n\n\n\n \n\n 22  \n \n\nO implante cir\u00fargico de uma pr\u00f3tese peniana pode ser considerado para pacientes que \n\nn\u00e3o respondem a farmacoterapia ou que desejam uma solu\u00e7\u00e3o permanente. As principais \n\ncomplica\u00e7\u00f5es do m\u00e9todo s\u00e3o falhas mec\u00e2nicas e infec\u00e7\u00e3o (3, 13, 19, 20).  \n\n \n\n1.4 O desenvolvimento de um novo medicamento \n\nO desenvolvimento de um novo medicamento \u00e9 um grande desafio. Desde a concep\u00e7\u00e3o \n\nda ideia at\u00e9 o registro de uma nova mol\u00e9cula o tempo despendido \u00e9 extremamente longo e a \n\ntaxa de sucesso \u00e9 muito baixa (21, 22). \n\n No Brasil, este desafio se torna ainda maior, gra\u00e7as a processos regulat\u00f3rios morosos e \n\ncultura de pesquisa e desenvolvimento ainda embrion\u00e1rios. No entanto, este cen\u00e1rio vem se \n\nmodificando rapidamente com a maior e efetiva participa\u00e7\u00e3o das universidades e \u00f3rg\u00e3os de \n\nfomentos governamentais importantes, como FINEP - Ag\u00eancia Brasileira da Inova\u00e7\u00e3o e \n\nBNDES \u2013 Banco Nacional do Desenvolvimento Econ\u00f4mico e Social (23).  \n\nUma inven\u00e7\u00e3o nem sempre se tornar\u00e1 uma inova\u00e7\u00e3o, este conceito \u00e9 muito importante \n\npara que oriente grupos de pesquisa em nosso pa\u00eds.   \n\nSe uma inven\u00e7\u00e3o n\u00e3o \u00e9 apropriada comercialmente para gerar valor de uso n\u00e3o se \n\ntornar\u00e1 uma inova\u00e7\u00e3o.  \n\nPara exemplificar, se a descoberta de nova entidade qu\u00edmica (inven\u00e7\u00e3o) n\u00e3o seguir os \n\npreceitos acima n\u00e3o se tornar\u00e1 um medicamento inovador (24). \n\nO desenvolvimento sem o foco na apropria\u00e7\u00e3o comercial entra no processo de \n\nesquecimento e n\u00e3o melhora a qualidade de vida da popula\u00e7\u00e3o. No entanto uma inven\u00e7\u00e3o, \n\nmesmo n\u00e3o se transformando em uma inova\u00e7\u00e3o, pode gerar conhecimento para que outras \n\npossam ser verdadeiras inova\u00e7\u00f5es no futuro (25).  \n\n\n\n \n\n 23  \n \n\nAs inova\u00e7\u00f5es s\u00e3o classicamente descritas como radical e incremental. As radicais \n\ncostumam mudar paradigmas, enquanto que as incrementais est\u00e3o relacionadas \u00e0 melhoria da \n\nqualidade e aperfei\u00e7oamento de produtos, processos e servi\u00e7os. Apesar de sua complexidade \n\nmenos aparente, as inova\u00e7\u00f5es incrementais s\u00e3o necess\u00e1rias, tanto para melhorar a qualidade \n\nde vida da popula\u00e7\u00e3o, como para gerar ideias que poder\u00e3o levar a uma inova\u00e7\u00e3o radical (23). \n\nNas ci\u00eancias da sa\u00fade, especialmente na medicina, estes conceitos s\u00e3o bastante \u00fateis. \n\nAtualmente, toda inova\u00e7\u00e3o incremental \u00e9 avaliada em rela\u00e7\u00e3o ao seu custo-efetividade, \n\ncomparada aos tratamentos tradicionais. A farmacoeconomia hoje \u00e9 uma ci\u00eancia e auxilia na \n\ndecis\u00e3o de utiliza\u00e7\u00e3o de um novo medicamento, tanto pelo m\u00e9dico, como, e principalmente, \n\nem termos de sa\u00fade p\u00fablica (26, 27). \n\nEm rela\u00e7\u00e3o ao tempo, custo e riscos inerentes processo inovador de um novo \n\nmedicamente, sabe-se que;  \n\nSe construirmos um gr\u00e1fico onde em X plotamos o tempo de desenvolvimento (fases) e \n\nno Y o risco, observaremos que no in\u00edcio do processo o tempo e custo s\u00e3o menores, no \n\nentanto o risco \u00e9 maior. Em contrapartida, em fases mais tardias do desenvolvimento \u2013 ap\u00f3s a \n\nprova de conceito e estudos pr\u00e9-cl\u00ednicos \u2013 esta rela\u00e7\u00e3o se inverte, o tempo e principalmente os \n\ncustos aumentam exponencialmente.   \n\nQuando se fala em medicamentos, sabe-se que de cada 10.000 mol\u00e9culas prospectadas, \n\n10 a 20 terminam satisfatoriamente os estudos pr\u00e9-cl\u00ednicos, de 1 a 5 iniciam a fase de estudos \n\ncl\u00ednicos e apenas uma ser\u00e1 efetivamente aprovada pelos \u00f3rg\u00e3os regulat\u00f3rios (24).  \n\nAinda, acontecimentos recentes demonstram que, na fase IV o monitoramento da \n\nfarmacovigil\u00e2ncia e estudos de farmacoepidemiolgia podem retirar um medicamento do \n\nmercado por quest\u00f5es de risco sanit\u00e1rio, n\u00e3o detectados nas fases de estudos cl\u00ednicos I, II e II. \n\n\n\n \n\n 24  \n \n\n Atualmente, tornou-se mais f\u00e1cil demonstrar a efic\u00e1cia de um medicamento do que \n\ngarantir a sua seguran\u00e7a.  \n\n \n\n1.4.1 Estudos cl\u00ednicos: fase I; II, III e IV. \n\nUm novo medicamento, antes de iniciar a fase de estudos cl\u00ednicos passa por estudos pr\u00e9-\n\nc\u00ednicos, in vitro e em animais.  \n\nO objetivo destes estudos \u00e9 determinar o poss\u00edvel mecanismo de a\u00e7\u00e3o de um novo \n\nmedicamento, a efic\u00e1cia e principalmente a seguran\u00e7a para que o mesmo possa ser testado em \n\nseres humanos. Nesta fase se determina a dose segura que se iniciar\u00e1 os estudos cl\u00ednicos fase \n\nI.  \n\n\u201cUm ensaio cl\u00ednico \u00e9 um estudo sistem\u00e1tico de medicamentos e/ou especialidades \n\nmedicinais em volunt\u00e1rios humanos que seguem estritamente as diretrizes do m\u00e9todo \n\ncient\u00edfico. Seu objetivo \u00e9 descobrir ou confirmar os efeitos e/ou identificar as rea\u00e7\u00f5es \n\nadversas ao produto investigado e/ou estudar a farmacocin\u00e9tica dos ingredientes ativos, de \n\nforma a determinar sua efic\u00e1cia e seguran\u00e7a\u201d (28). \n\nOs ensaios cl\u00ednicos s\u00e3o realizados, na maioria das vezes, para o desenvolvimento de \n\nnovos medicamentos.  \n\nS\u00e3o classicamente divididos em:  \n\n Fase I \u2013 onde se avalia a tolerabilidade, seguran\u00e7a e farmacocin\u00e9tica de um \n\nmedicamento, geralmente s\u00e3o conduzidos em volunt\u00e1rios saud\u00e1veis. \n\nFase II \u2013 conduzidos em pacientes portadores da patologia a qual o medicamento se \n\ndestinar\u00e1, geralmente o n\u00famero de volunt\u00e1rios n\u00e3o \u00e9 muito elevado e o objetivos destes \n\nestudos \u00e9 avaliar a efic\u00e1cia e principalmente a seguran\u00e7a do novo medicamento. \n\n\n\n \n\n 25  \n \n\nFase III - s\u00e3o estudos terap\u00eauticos com um n\u00famero maior de doentes, para determina\u00e7\u00e3o \n\ndo risco-benef\u00edcio do tratamento.  \n\n Fase IV \u2013 estudos tamb\u00e9m conhecidos como p\u00f3s-marketing onde o objetivo \u00e9 \n\nacompanhar o medicamento no mercado, visando principalmente o perfil de seguran\u00e7a do \n\nnovo medicamento (29). \n\n \n\nEstudo Cl\u00ednico Fase I  \n\nOs estudos de Fase I, como j\u00e1 sumarizado acima, t\u00eam como objetivo testar a \n\ntolerabilidade, seguran\u00e7a e perfil farmacocin\u00e9tico de um novo medicamento. \n\nComo \u00e9 o primeiro estudo onde seres humanos ser\u00e3o expostos, o delineamento deste \n\ndeve levar sempre em considera\u00e7\u00e3o os dados de estudos pr\u00e9-cl\u00ednicos, principalmente \n\nrelacionados \u00e0s doses que apresentaram toxicidade nos modelos animais estudados. \n\nExistem v\u00e1rias maneiras de se calcular a dose inicial que ser\u00e1 utilizada no estudo cl\u00ednico \n\nfase I.  \n\nO preconizado em v\u00e1rios guidelines e na literatura, inicialmente, calcula-se a dose \n\nm\u00e1xima inicial (MRSD - maximum recommended starting dose -) \u2013 que \u00e9 calculada ap\u00f3s a \n\ndetermina\u00e7\u00e3o da dose equivalente human (HED - human equivalent dose), que por sua vez \u00e9 \n\ncalculada utilizando-se a NOAEL- no observed adverse effect levels \u2013 da esp\u00e9cie animal mais \n\nadequada, dentre as testadas durante a fase pr\u00e9-clinica. Em seguida se aplica um fator de \n\nseguran\u00e7a, uma fra\u00e7\u00e3o da HED, dependendo da classe do novo medicamento e do perfil de \n\nseguran\u00e7a esperado em seres humanos (30, 31, 32). \n\nEm seguida, o delineamento de um estudo fase I deve prever um escalonamento para \n\natingir, se poss\u00edvel, a dose m\u00e1xima tolerada, MTD - maximum tolerable dosage. Existem \n\n\n\n \n\n 26  \n \n\nalguns modelos estat\u00edsticos para se aplicar ao escalonamento da dose, ou seja, as doses \n\nsubsequentes \u00e0 inicial, calculada conforme descrido acima. \n\nHabitualmente, se utiliza para estabelecer a pr\u00f3xima dose, em um estudo de \n\nescalonamento de dose, a sequ\u00eancia de Fibonacci. Esta foi formulada por Leonardo Pisano em \n\n1202 em um de seus problemas (problema dos coelhos) descritos no cl\u00e1ssico Liber Abbaci, \n\nconsiderado um dos melhores tratados de aritm\u00e9tica e \u00e1lgebra. \n\nEsta sequ\u00eancia, definida como, 1, 1, 2, 3, 5, 8, 13, 21, 34, 55, 89, 144,... \u00e9 obtida, a \n\npartir do terceiro n\u00famero, pela soma dos dois antecessores. Simplificadamente pode ser obtida \n\nmultiplicando-se o termo anterior por 1,618 (33, 34). \n\nAinda, \u00e9 importante estabelecer uma regra de escalonamento da dose que garanta \n\nseguran\u00e7a ao sujeito de pesquisa. Em estudos com medicamentos oncol\u00f3gicos esta regra \u00e9 \n\nbastante criteriosa, detalhada e padronizada, pois estes estudos cl\u00ednicos envolvem \n\nmedicamentos com alto grau de toxicidade.  \n\n Esta regra leva em considera\u00e7\u00e3o a dose limite de toxicidade (DLT- dose-limiting \n\ntoxicity), definida como a dose que apresenta acima de grau 3 de toxicidade, exceto \n\nneutropenia de grau 3, acompanhados ou n\u00e3o por febre ou infec\u00e7\u00e3o. \n\n A escala em quest\u00e3o \u00e9 a crit\u00e9rio comum de toxicidade (CTC - common toxicity criteria) \n\npadronizada pelo Cancer Therapy Evaluation Program. Este crit\u00e9rio estabelece varia\u00e7\u00f5es de \n\ngravidade do evento adverso observado entre 0 e 4 e os categoriza por sistemas/\u00f3rg\u00e3os. \u00c9 \n\nutilizada na avalia\u00e7\u00e3o de eventos adversos durante o tratamento oncol\u00f3gico e em estudos \n\ncl\u00ednicos envolvendo medicamentos desta classe, como j\u00e1 salientado (35). \n\nResumidamente, a regra segue o seguinte esquema:  \n\n- Inicialmente, organiza-se uma coorte de 3-6 volunt\u00e1rios por dose. Hipoteticamente \n\nutilizaremos uma coorte de 3 volunt\u00e1rios para exemplificar. \n\n\n\n \n\n 27  \n \n\nTr\u00eas volunt\u00e1rios s\u00e3o tratados com a dose inicial. Se, pelo menos, dois pacientes \n\napresentam sinais de DLT, a dose pr\u00e9via \u00e9 definida como a dose m\u00e1xima tolerada (MTD). Se \n\nnenhum dos 3 pacientes apresentam sinais e sintomas de DLT, a dose \u00e9 aumentada para etapa \n\nseguinte em uma nova coorte de 3 volunt\u00e1rios, onde os crit\u00e9rios anteriores ser\u00e3o utilizados. Se \n\nnenhum dos tr\u00eas pacientes tratados apresentam sinais e sintomas de DLT, 3 pacientes \n\nadicionais s\u00e3o tratados com a dose atual. Se nenhum destes 3 volunt\u00e1rios adicionais \n\napresentam sinais e sintomas de  DLT, a dose \u00e9 aumentada para o pr\u00f3ximo grupo de 3 \n\npacientes e o processo continua. A MTD \u00e9 considerada como atingida quando pelo menos 2 \n\npacientes de um total de 6 pacientes s\u00e3o tratados (30). \n\nApesar do perfil de seguran\u00e7a de outras classes de medicamentos, em geral , ser mais \n\nfavor\u00e1vel, m\u00e9todos de escalonamento de doses seguros devem sempre ser adotados, baseados \n\nnos resultados de estudos anteriosres n\u00e3o cl\u00ednicos e perfil de seguran\u00e7a da classe \n\nfarmacol\u00f3gica a que pertence o novo medicamento, quando poss\u00edvel (31, 36, 37). \n\n \n\n1.5 Estudos preliminares com o Carbonato de lodenafila  \n\nCom o objetivo de pesquisar a possibilidade de um an\u00e1logo da sildenafila com maior \n\npot\u00eancia, seletividade e melhor perfil de seguran\u00e7a, foram sintetizados pelo Dipartimento di \n\nChimica Farmac\u00eautica da Universit\u00e0 di Napoli \u201cFederico II\u201d, vinte mol\u00e9culas (6 a-v), \n\ncaracterizados pela presen\u00e7a de um grupo sulfonil ou de um substituinte n\u2019n\u2019etilendiamina na \n\nposi\u00e7\u00e3o do grupo metil da piperazina. Estes an\u00e1logos foram testados no departamento de \n\nfarmacologia da Faculdade de Ci\u00eancias M\u00e9dicas \u2013 UNICAMP. \n\nEm plaquetas e m\u00fasculo liso h\u00e1 elevada concentra\u00e7\u00e3o de PDE5, \u00e9 por este motivo que \n\nensaios funcionais e bioqu\u00edmicos em plaquetas e m\u00fasculo liso t\u00eam sido bastante usados para o \n\ndesenvolvimento de novos medicamentos visando seletividade na degrada\u00e7\u00e3o do GMPc. \n\nSendo assim, a metodologia adotada para testar estes an\u00e1logos e selecionar os mais vi\u00e1veis \n\n\n\n \n\n 28  \n \n\npara o desenvolvimento de um novo medicamento inibidor da PDE5 foi utilizar, os seguintes \n\nensaios: a atividade inibit\u00f3ria da PDE5 de plaquetas humanas, o efeito relaxante dos an\u00e1logos \n\ndo sildenafila em corpo cavernoso de coelho e o efeito relaxante dos an\u00e1logos do sildenafila \n\nem an\u00e9is de aorta de coelho. Nos estudos com plaquetas para avaliar a atividade inibit\u00f3ria da \n\nPDE5 foi utilizado sangue de volunt\u00e1rios sadios. Nos estudos funcionais foram utilizados \n\ncoelhos New Zealand machos (2-3 kg) procedentes do CEMIB-UNICAMP (38). \n\nOs compostos 6m, 6n e 6q demonstraram valores elevados de concentra\u00e7\u00e3o efetiva 50% \n\n(IC50) para inibir a PDE5 plaquet\u00e1ria. Os 6a, 6b, 6d, 6g e 6p produziram inibi\u00e7\u00e3o inferior a \n\n50%. A IC50 dos compostos 6c, 6e, 6f, 6h, 6l e 6o foram similares ao da sildenafila. \n\nNos estudos funcionais, todos an\u00e1logos da sildenafila, exceto o 6m, relaxaram \n\nprepara\u00e7\u00f5es de corpo cavernoso de coelho de maneira dependente da concentra\u00e7\u00e3o.  \n\nO an\u00e1logo 6f demonstrou o melhor perfil farmacol\u00f3gico no relaxamento, com pot\u00eancia \n\nsimilar ao sildenafila. \n\nV\u00e1rios dos an\u00e1logos testados demonstraram ser mais lipof\u00edlicos do que o sildenafila. \n\nEstes achados podem contribuir para o desenvolvimento de medicamentos para patologias que \n\napresentem disfun\u00e7\u00e3o endotelial em sua etiopatogenia.  \n\nDando continuidade \u00e0 defini\u00e7\u00e3o da melhor mol\u00e9cula para atingir os objetivos propostos, \n\navaliaram-se os efeitos dos an\u00e1logos hidroxisetilildenafil, e os d\u00edmeros, carbonato, ureia e \n\nuretano. Estudou-se tamb\u00e9m o efeito m\u00e1ximo 50% (EC50), antilog da concentra\u00e7\u00e3o de droga \n\nnecess\u00e1ria para produzir 50% do efeito m\u00e1ximo (pEC50) em corpo cavernoso de rato e c\u00e3es \n\nda ra\u00e7a beagle, a estabilidade e metaboliza\u00e7\u00e3o dos d\u00edmeros no plasma de rato, humano e c\u00e3o. \n\nAvaliou-se tamb\u00e9m a farmacocin\u00e9tica dos d\u00edmeros em c\u00e3o e o efeito da administra\u00e7\u00e3o \n\nendovenosa sobre a press\u00e3o arterial e frequ\u00eancia card\u00edaca em c\u00e3es da ra\u00e7a beagle.  \n\n\n\n \n\n 29  \n \n\nCom base nos resultados obtidos foi decidido que o d\u00edmero hidroetilsildenafil (em sua \n\nforma carbonato) foi o mais indicado para a pr\u00f3xima etapa da avalia\u00e7\u00e3o da toxicidade pr\u00e9-\n\ncl\u00ednica (38, 39, 40). \n\nA patente do composto denominado CRIS035 foi depositada pelo laborat\u00f3rio Crist\u00e1lia \n\nProdutos Qu\u00edmicos Farmac\u00eauticos Ltda. durante a fase experimental.  \n\n1.5.1 Estudos pr\u00e9-cl\u00ednicos de toxicidade \n\nForam realizados os ensaios de atividade mutag\u00eanica in vitro (Teste de Ames), estudos \n\nde toxicidade aguda em roedor (ratos) e estudos em um roedor (rato) e um n\u00e3o roedor (c\u00e3o) \n\ncom dura\u00e7\u00e3o de 14 dias.  \n\nNo teste de Ames concluiu-se que:  \n\n- O composto CRIS031 n\u00e3o demonstrou efeitos mutag\u00eanicos sobre as  linhagens TA 98, \n\nTA 100, TA 1535 e TA 1537 de Salmonella typhimurium testadas na presen\u00e7a ou na aus\u00eancia \n\nda  fra\u00e7\u00e3o microssomal metabolicamente ativa S9 de f\u00edgado de rato. \n\nNa toxidade aguda em ratos concluiu-se que: \n\n- Em condi\u00e7\u00f5es experimentais a dose oral DL50 do teste \u00e9 maior do que 2000mg/Kg. \n\nN\u00e3o foram observados sinais de toxicidade nestas doses.  \n\nEstudo de toxicidade de doses repetidas duas semanas em ratos com doses orais \n\n(Gavagem):  \n\n- N\u00e3o foram observados sinais de toxicidade em doses de tolerabilidade m\u00e1xima (MTD) \n\nde 1000 mg/Kg. \n\nEstudo de toxidade em doses repetidas em 2 semanas por via oral (Gavagem) em c\u00e3es \n\n(Beagle):  \n\n- N\u00e3o foram observados sinais de toxicidade em doses de 1000 mg/Kg \n\n\n\n \n\n 30  \n \n\nAvalia\u00e7\u00e3o sobre a atividade do sistema nervosa central ap\u00f3s dose oral \u00fanica (gavagem) \n\nem roedores (ratos):  \n\n- Nenhuma mortalidade ou morbidade foi observada ap\u00f3s a administra\u00e7\u00e3o de doses \n\n\u00fanicas (100, 550,775 e 1000 mg/Kg). \n\n- Nenhum dist\u00farbio do comportamento foi observado, utilizando-se o functional \n\nobservation battery (FOB).  \n\n- Nenhuma altera\u00e7\u00e3o macrosc\u00f3pica foi observada - post-mortem (38, 39, 40).  \n\n \n\n1.6 Objetivo  \n\n \n\nO estudo foi conduzido para avaliar a seguran\u00e7a, tolerabilidade e farmacocin\u00e9tica do \n\ncarbonato de lodenafil ap\u00f3s administra\u00e7\u00e3o em doses crescentes (1 a 100 mg), em dose \u00fanica, \n\nem volunt\u00e1rios saud\u00e1veis. \n\n \n\n \n\n \n\n \n\n \n\n \n\n \n\n \n\n \n\n\n\n \n\n 31  \n \n\n2. Cap\u00edtulo I \n\n \n\nA phase I clinical trial of lodenafil carbonate, a new phosphodiesterase type 5 \n\n(PDE5) inhibitor, in healthy male volunteers. \n\nGustavo D. Mendesb, c*, Hilton Oliveira dos Santos Filhoa, Alberto dos Santos Pereirad, \n\nFabiana D. Mendesa, Jaime O. Ilhad, Khalid M. Alkharfye &amp; Gilberto De Nuccie,f \n\n \n\naDepartment of Internal Medicine, State University of Campinas, Campinas/SP, Brazil \n\nbDepartment of Pharmacology, Faculty of Medical Sciences, State University of Campinas \n\n(UNICAMP), Campinas/SP, Brazil  \n\ncFaculty of Odontology, University Camilo Castelo Branco (UNICASTELO), S\u00e3o Paulo, SP, \n\nBrazil \n\ndGaleno Research Unit, Latino Coelho St., 1301, Parque Taquaral, 13087-010, Campinas, SP, \n\nBrazil  \n\neDepartment of Clinical Pharmacy, College of Pharmacy, King Saud University, Riyadh, \n\nSaudi Arabia \n\nfDepartment of Pharmacology, Institute of Biomedical Sciences, University of Sao Paulo, S\u00e3o \n\nPaulo, Brazil. \n\n \n\nRunning title: Lodenafil carbonate phase I study. \n\n*Corresponding author \n\n415 Jesu?no Marcondes Machado Ave.,  \n\n\n\n \n\n 32  \n \n\n13092-320, Campinas - SP, Brazil.  \n\nTel.: +55-193251-6928; fax: +55-19-3252-1516.  \n\nE-mail: gugamendes@terra.com.br \n\n \n\nAbstract  \n\nLodenafil carbonate is a new phosphodiesterase type 5 (PDE5) inhibitor used in \n\ntreatment of erectile dysfunction. Objective: The present study was conducted to evaluate the \n\nsafety, tolerability, and pharmacokinetics of lodenafil carbonate after administering ascending \n\n(1 to 100 mg) single oral doses to healthy male volunteers (n=33). Methods: The study was an \n\nopen-label, dose-escalation, phase I clinical trial involving the administration of single oral \n\ndoses of lodenafil carbonate. Lodenafil carbonate was administered sequentially, escalating in \n\nsingle doses of 1 mg to 100 mg with a washout period of at least 1 week between each dose. \n\nThe progression to the next dose was allowed after clinical and laboratory exams, Ambulatory \n\nMonitoring of Arterial Pressure (AMAP) without relevant clinical modifications and adverse \n\nevents without clinical relevancy. Blood samples were collected at pre-dose, 0.25, 0.5, 0.75, \n\n1, 1.25, 1.5, 1.75, 2, 2.5, 3, 3.5, 4, 4.5, 5, 6, 7, 8, 10, 12, 14, 16, 20 and 24h post-dosing. \n\nPlasma samples for measurement of lodenafil carbonate and lodenafil were analyzed by liquid \n\nchromatography coupled to tandem mass spectrometry. Results: No serious adverse events \n\nwere observed, and none of the subjects discontinued the study due to intolerance. The \n\nAMAP measurements, clinical and laboratory exams and ECG revealed no significant \n\nchanges even at higher doses. Lodenafil carbonate was not detected in any samples, indicating \n\nthat it acts as a pro-drug. The mean lodenafil pharmacokinetic parameters for tmax and t1/2 \n\nwere 1.6 (\u00b10.4) hr and 3.3 (\u00b11.1) hr, respectively. This study demonstrated that lodenafil \n\ncarbonate was well tolerated and showed a good safety profile in healthy male volunteers. \n\n\n\n \n\n 33  \n \n\nKey words: phosphodiesterase type 5 (PDE5) inhibitor, pharmacokinetics, safety \n\n \n\n 1. Introduction \n\nLodenafil carbonate is a new phosphodiesterase type 5 (PDE5) inhibitor for treatment of \n\nerectile dysfunction [1]-[4], a common sexual problem for males over 40-50 years of age.  \n\nLodenafil relaxes isolated human and animal cavernous tissues through inhibition of cyclic \n\nguanosine monophosphate hydrolysis [1]. Lodenafil carbonate was approved by Brazilian \n\nSanitary Surveillance Agency (ANVISA) in 2007 [5].  \n\nThe pharmacokinetic parameters for lodenafil carbonate and lodenafil following oral \n\nadministration (10 mg) of lodenafil carbonate in male beagle dogs were (mean\u00b1S.D): \n\nlodenafil carbonate: 11\u00b114 ng/mL, 23\u00b121 ng*h/mL, 2.1\u00b13.0 h, 1.67\u00b11.53 h; lodenafil: \n\n1357\u00b1961 ng/mL, 9,091\u00b15,526 ng*h/mL, 4.3\u00b10.5 h, 4.3\u00b10.5 h for Cmax, AUC, t1/2, tmax, \n\nrespectively [1]. The above results indicate that lodenafil carbonate acts as a prodrug, \n\ndelivering lodenafil in vivo as the active moiety, since very small amounts of lodefanil \n\ncarbonate reached the systemic circulation. \n\nThe tmax for PDE5 inhibitors is between 0.33 \u2013 1.8 hours (sildenafil 1 h, tadalafil 1.8 h, \n\nvardenafil 0.75 h, udenafil 1 h and avanafil 0.33 h) and the half-life time for PDE5 inhibitors \n\nvaries from 2.6 to 21.1 hours ( sildenafil 2.76 h, vardenafil 2.63 h, avanafil 5.36 h, udenafil 11 \n\nh and tadalafil 21.1 h) [6]-[10]. After single oral administrations of lodenafil carbonate (160 \n\nmg) in healthy male volunteers, lodenafil  is rapidly absorbed with peak of concentration (157 \n\nng/mL) occurring at ? 1.2 hours, half-life time of 2.4 hours and area under the curve (AUC) \n\nof 530 ng*h/mL [4]. \n\n\n\n \n\n 34  \n \n\nThe present study was conducted to evaluate the safety, tolerability, and \n\npharmacokinetics of lodenafil carbonate after administering ascending (1 to 100 mg) single \n\noral doses in normal healthy male volunteers.  \n\n \n\n2. Materials and methods \n\n2.1. Clinical protocol \n\nThe following inclusion criteria were used: Thirty-three healthy male volunteers, aged \n\nbetween 18 and 55 years old and within ? 19 and ? 28.75 of the ideal body weight were \n\nselected for the study [11]. The volunteers were selected for the study after having their health \n\nstatus previously assessed by a clinical evaluation and laboratory tests (biochemical and \n\nhematological parameters, and urinalysis). The volunteers were free from significant cardiac, \n\nhepatic, renal, pulmonary, neurological, gastrointestinal and hematological diseases, as \n\nassessed by clinical examination, ECG and the following laboratory tests: blood glucose, \n\nurea, creatinine, AST, ALT, alkaline phosphatase, ?GT, total bilirrubin and fractions, uric \n\nacid, total cholesterol, triglycerides, albumin and total protein, hemoglobin, hematocrit, total \n\nand differential white cell counts and routine urinalysis. All subjects were negative for HIV, \n\nHBV (except for serological scar) and HCV. The subjects were able to comprehend the full \n\nnature and purpose of the study, including possible risks and side effects and were willing to \n\ncooperate with the Investigator and comply with the requirements of the entire study. All \n\nsubjects provided signed consent forms. \n\nThe following exclusion criteria were used: laboratory values outside the accepted \n\nnormal ranges, unless considered not clinically significant by the investigator; participation in \n\nan experimental study or had ingested an experimental drug three months prior to the \n\ninitiation of the study; any significant clinical illness or surgery within eight weeks \n\n\n\n \n\n 35  \n \n\nimmediately prior to the initiation of the study or maintenance therapy with any drug; \n\nhospitalizing for any reason within eight weeks prior to the initiation of the study; history of \n\ndrug, medication or alcohol abuse, or had ingested alcohol within 48 hours prior to the \n\nbeginning of the confinement portion of the study; history of hepatic, renal, epileptic or \n\nhemopoietic disease; hypo or hypertension of any etiology (outside the range of 100-140 \n\nmmHg for systolic and 60-90 mmHg for diastolic blood pressure), or heart rate not between \n\n50-90 bpm; myocardial infarction, angina pectoris and/or congestive heart failure; the subject \n\nhad donated or lost blood within three months prior to the study or more than 1500mL within \n\n12 months preceding the study; any other condition as per investigator judgment; high \n\ncaffeine intake (more than 5 cups of tea or coffee/day); subject who smoked; history or \n\npresence of gastrointestinal, liver or kidney disease or any other condition known to interfere \n\nwith the absorption, distribution, metabolism or excretion of drugs.  \n\nConcomitant medication was to be avoided where possible during the study. Any \n\nmedication, including over-the-counter medication, was to be recorded. \n\nThe male volunteers had the following clinical characteristics (mean \u00b1 SD [range]): age \n\n31.1\u00b1 5.7 yr. [23 \u2013 40]; height 174 \u00b1 6.1 cm [160.0 \u2013 184.0]; body weight 71.2 \u00b1 9.7 kg [54.5 \n\n\u2013 90.5]. All subjects provided written informed consent, and the Ethics Committee of the \n\nState University of Campinas approved the protocol. Any major changes required approval \n\nfrom the Committee. The study was conducted in accordance with Good Clinical Practices \n\nand provisions of the Declaration of Helsinki (1964) and all revisions.  \n\nAfter screening and a washout period (of at least 2 weeks), the individuals who \n\nqualified were confined for 3 periods of approximately 40 hours. Each confinement was \n\nintervaled for 1 week. The study was conducted in an open, randomized, dose-escalation, \n\nthree-period open-label experimental design, involving the administration of increasing single \n\n\n\n \n\n 36  \n \n\noral doses (1 mg, 2 mg, 3 mg, 5 mg, 8 mg, 10 mg, 20 mg, 30 mg, 50 mg, 80 mg, 100 mg) of \n\nlodenafil carbonate (Table 1). A Fibonacci-like scheme was used for dose escalation (from 1-\n\n10, and from 10-100 mg). The progression to the next dose was allowed by clinical and \n\nlaboratory exams, Ambulatory Monitoring of Arterial Pressure (AMAP) without relevant \n\nclinical modifications, and adverse events without clinical relevancy. The adverse event \n\nevaluation was performed during confinement period and in a clinical visit 24h before the \n\nnext confinement. The medical investigator classified the event intensity as mild, moderate, \n\nsevere, and serious, and the causal relationship to the formulation as unrelated, unlikely, \n\npossible and probable.  \n\nDuring each period, the volunteers were hospitalized between 4:00 and 7:00 p.m., \n\nhaving already eaten a normal evening meal. After overnight fasting, they received at 7:00 \n\na.m., a single dose of appropriate lodenafil carbonate (tablet) along with 240 ml of tap water. \n\nAll volunteers were required to remain fasting until 2 hours after dose administration, when a \n\nxanthine-free standard breakfast was available. A xanthine-free standard lunch was provided \n\nfive (lunch), eight (afternoon snack), twelve (lunch) and fifteen (supper) hours after dose. A \n\nstandard meal (lunch) of rice, beans, vegetables, and fried chicken, plus a fruit as dessert was \n\nconsumed. The breakfast, afternoon snack and supper included crackers, bread, jelly, cake and \n\napple. No other food was permitted during the \"in-house\" period and liquid consumption was \n\nallowed ad libitum after lunch (with the exception of xanthine-containing drinks, including \n\ntea, coffee, and cola). No comedication was permitted during the study. \n\nBlood samples (5 mL) from a suitable antecubital vein were collected by an indwelling \n\ncatheter into heparin containing tubes at pre-dose, 0.25, 0.5, 0.75, 1, 1.25, 1.5, 1.75, 2, 2.5, 3, \n\n3.5, 4, 4.5, 5, 6, 7, 8, 10, 12, 14, 16, 20 and 24h post-dosing. \n\n\n\n \n\n 37  \n \n\nThe Ambulatory Monitoring of Arterial Pressure (AMAP) was measured for 24 hours \n\nafter drug administration, with 15-minute intervals in the first two hours and then every hour \n\nuntil the end of the internment (24 hours after the administration of the lodenafil carbonate). \n\nTwo ECGs were obtained one hour and twelve hours after the administration of the lodenafil \n\ncarbonate.  \n\n \n\n2.2 Formulations \n\nThe following formulations were employed: lodenafil carbonate test formulation tablet \n\nin 1 mg (lot 318/04), 2 mg (lot 319/04), 3 mg (lot 320/04), 5 mg (lot 321/04), 8 mg (lot \n\n378/04), 10 mg (lot 379/04), 20 mg (lot 392/04), 30 mg (lot 391/04), 50 mg (lot 394/04), 80 \n\nmg (lot 396/04) and 100 mg (lot 397/04) from Crist\u00e1lia Produtos Qu\u00edmicos e Farmac\u00eauticos \n\nLtda, Itapira, Brazil. \n\n \n\n2.3 Chemicals and reagents \n\nLodenafil carbonate (lot number: SL24-024), lodenafil (lot number: not available), \n\nsildenafil (lot number: 20227/99) were provided by Crist\u00e1lia Produtos Qu\u00edmicos e \n\nFarmac\u00eauticos Ltda, Itapira, Brazil. Acetonitrile, formic acid and methanol were purchased \n\nfrom J. T. Baker, USA. Diethyl ether and hexane were purchased from Mallinckrodt, USA. \n\nBlank human blood was collected from healthy, drug-free volunteers. Plasma was obtained by \n\ncentrifugation of blood treated with sodium heparin. Pooled plasma was prepared and stored \n\nat approximately -20 \u00baC until needed. \n\n \n\n \n\n\n\n \n\n 38  \n \n\n2.4 Calibration standards and quality controls \n\nStock solutions of lodenafil carbonate, lodenafil and the internal standard (sildenafil) \n\nwere prepared in acetonitrile/water (50/50, v/v) at concentrations of 1 mg/mL. Calibration \n\ncurves of lodenafil carbonate and lodenafil were prepared by spiking blank plasma at \n\nconcentrations of 0.5, 1.0, 5.0, 20.0, 50.0, 200, 1,000 and 2,000 ng/mL and each concentration \n\nwas analyzed in duplicate. The quality control samples were prepared in blank plasma at \n\nconcentrations of 3, 30, 180 and 1,800 ng/mL (QCA, QCB, QCC and QCD, respectively). \n\nThe spiked plasma samples (standards and quality controls) were extracted in each analytical \n\nbatch along with the unknown samples. \n\n \n\n2.5 Drug analysis \n\nThe blood samples (5 mL) were centrifuged at 2500 g for 10 min at -4oC and the plasma \n\ndecanted and stored at \u2013200 C until assayed for lodenafil carbonate and lodenafil contents. \n\nLodenafil carbonate, lodenafil, and the IS were extracted from plasma samples and quantified \n\nby liquid chromatography tandem mass spectrometry (LC-MS-MS) with positive electrospray \n\nionization using multiple reaction monitoring (MRM). \n\nBriefly, 0.2 mL of each plasma sample was pipetted into a glass tube followed by 0.05 \n\nmL of the internal standard solution (1,000 ng/mL of sildenafil (Crist\u00e1lia Produtos Qu\u00edmicos e \n\nFarmac\u00eauticos Ltda, Itapira, Brazil.) and 4 mL of hexane/diethyl-ether (20/80; v/v) (HPLC \n\ngrade, J. T. Baker, Phillipsburg, NJ, USA). The tubes were briefly vortex-mixed (40 s). The \n\nupper organic layers were removed and transferred into another sterile tube, and evaporated to \n\ndryness under N2 (at 40 \u00baC). The dry residues were dissolved with 0.2 mL of \n\nacetonitrile/water (50/50; v/v) and the solutions were transferred to glass microvials using \n\n\n\n \n\n 39  \n \n\nautomatic pipettes with disposable plastic tips. The vials were caped and placed into the \n\nautosampler racks. \n\nHigh performance liquid chromatography (HPLC) was performed on C18, 4 mm (100 x \n\n2.1 mm i.d. (Jones Chromatography, Genesis, USA) at a flow rate of 0.45 mL/min and \n\npressure of the system was approximately 120 bar. The mobile phase was acetonitrile/water \n\n(90/100; v/v) + 0.1% formic acid (Analysis Grade, J. T. Baker, USA).  The column operated \n\nat room temperature. The temperature of the auto sampler operated at 10 \u00b1 2 oC and the \n\ninjection volume was 10 \u00b5L. \n\nTypical standard retention times were 1.1 \u00b1 0.2 min for lodenafil carbonate, 0.8 \u00b1 0.1 \n\nmin for lodenafil and 0.8 \u00b1 0.1 min for the IS, and the total run-time was 2.4 min. The mass \n\nspectrometer (model API 4000, Sciex/Applied Biosystems, Foster City, CA, USA) equipped \n\nwith a turbospray source using a crossflow counter electrode, was run in positive mode (ES+) \n\nwith multiple reaction monitoring (MRM). The mass spectrometer was set as follows: 1035.2 \n\n> 487.1, 505.2 > 487.0 and 475.1 >283.2, for lodenafil carbonate, lodenafil and sildenafil, as \n\nthe precursor ions and the respective product ions m/z. The limit of quantification in plasma \n\nwas 0.5 ng/mL for both lodenafil carbonate and lodenafil. \n\n \n\n2.6 Assay performance \n\nA linear regression with a weighting index of 1/x^2 was performed on the peak area \n\nratios of lodenafil carbonate and the internal standard versus the lodenafil carbonate \n\nconcentrations of eight human plasma standards (in duplicate) to generate a calibration curve. \n\nA linear regression with a weighting index of 1/x^2 was performed on the peak area ratios of \n\nlodenafil and the internal standard versus the lodenafil concentrations of the eight human \n\nplasma standards (in duplicate) to generate a calibration curve. \n\n\n\n \n\n 40  \n \n\nPrecision and accuracy: Within- and between-run precision was determined as the \n\nrelative standard deviation, RSD (%) = 100(SD/M), and the accuracy as the percentage \n\nrelative error, RE (%) = (E-T)(100/T), where M is the mean, SD is the standard deviation of \n\nM, E is the experimentally determined concentration and T is the theoretical concentration. \n\n \n\n2.7 Pharmacokinetics  \n\nIndividual plasma level-time curves were constructed and pharmacokinetic parameters \n\nwere obtained according to a non-compartmental approach. The first-order terminal \n\nelimination rate constant (ke) was estimated by linear regression from the points describing \n\nthe elimination phase in a log-linear plot, and the half-life (t1/2) was derived from this rate \n\nconstant (t1/2 = ln (2)/ke). The maximum plasma concentration (Cmax) and the time taken to \n\nachieve this concentration (tmax) were obtained directly from the curves. The areas under the \n\nlodenafil plasma concentration vs. time curves from time zero to the last detectable \n\nconcentration (AUClast) were calculated by applying the linear trapezoid rule. Extrapolation of \n\nthese areas to infinity (AUCinf) was done by adding the value Clast/ke to the calculated AUClast \n\n(where Clast = the last detectable concentration). Clearance (CL) was calculated by the \n\nformula dose/AUC0-inf. Volume of distribution (Vd) was calculated by the formula \n\nDose/Ke(AUCinf). The software used included WinNonLin Professional Network Edition \n\n(Scientific Consulting, v. 3.0), Microsoft Excel (v. 7.0) and GraphPad Prism (v. 3.02). \n\n \n\n3. Results  \n\nAll biochemical parameters monitored presented no clinically relevant alterations \n\nduring the phase I study. No significant changes were observed in the laboratory exams and in \n\nthe ECGs intra-study.  Tolerance of both formulations (1 to 100 mg) was good and no \n\n\n\n \n\n 41  \n \n\nsignificant adverse event were observed or reported. One volunteer had an adverse event \n\n(dysuria not related to therapy and classified as not serious) after the discharge of the third \n\nconfinement period during the phase I study. Two volunteers related spontaneous erections \n\nafter administration of lodenafil carbonate (30 and 50 mg): one during the clinical evaluation \n\nfor discharge of the study and one during the final clinical evaluation in the first period of \n\nconfinement. \n\nLaboratory tests after administration of lodenafil carbonate are shown in Table 4. Blood \n\npressure and heart rate were assessed for 24 hours after treatment with lodenafil carbonate \n\n(Figure 2; Table 5).  \n\nThe mean lodenafil plasma concentrations vs. time profiles after testing single oral \n\ndoses of lodenafil carbonate in males are shown in Figure 1. Calculated mean \n\npharmacokinetic parameters of lodenafil are given in Table 3.  \n\nThe method was linear for lodenafil carbonate and lodenafil concentrations from 0.5 to \n\n2000 ng/mL. No significant matrix effect was observed. The limit of quantification (LOQ), \n\ndefined as the lowest concentration at which both the precision and accuracy were&lt;20%, was \n\n0.5 ng/mL for lodenafil carbonate and lodenafil. The within- and between-run precision and \n\naccuracy for the quality controls are summarized in Table 2. \n\n \n\n4. Discussion \n\nHigh-performance liquid chromatography (HPLC) coupled with tandem mass \n\nspectrometry (LC-MS-MS) in animal and human plasma has been used for lodenafil and/or \n\nlodenafil carbonate quantification [1][4]. However, no full validation method has been \n\npreviously published for lodenafil and lodenafil carbonate quantification. Our method \n\nemployed sildenafil as internal standard instead of theophylline, having a shorter retention \n\n\n\n \n\n 42  \n \n\ntime of 1.1 min for lodenafil carbonate and 0.8 min for lodenafil. The limit of quantification \n\n(0.5 ng/ml) was adequate for pharmacokinetic evaluation of lodenafil carbonate and lodenafil.  \n\nThe results obtained following oral administration of lodenafil carbonate in healthy \n\nmale volunteers show that lodenafil carbonate acts as a prodrug when given orally, since no \n\nquantifiable lodefanil carbonate concentration has been detected in the systemic circulation. \n\nSimilar results were observed in male beagles following oral administration of lodenafil \n\ncarbonate [1].  \n\nThe adverse event of dysuria was evaluated as not serious since the volunteer \n\nspontaneously recovered and only reported in the medical final evaluation.  \n\nAfter the oral administration of the lodenafil carbonate 80 mg tablets to the volunteers, \n\nthe tmax (1.6h) and t1/2 (3.3h) were similar to the reported in the literature (tmax: 1.2 -1.5h; \n\nt1/2: 2.4 \u2013 3h) [2]. The Cmax (17.62 ng/mL) and AUC (42.80 hr*ng/mL) values were \n\ndifferent to those reported in the literature (Cmax 158 ng/mL; AUC 528 hr*ng/mL) for a \n\nlodenafil carbonate tablet (dose 160 mg; two tablets of 80 mg) formulation [2].  \n\nAs shown in Table 3, the pk parameters calculated for 1 mg are not reliable due to low \n\nplasma lodenafil after a dose of 1 mg. The major differences for t1/2, Cl and Vd over the dose \n\nrange can be explained by the low number (n=3 to 1 mg; n=6 to 2mg and n=9 between 3 mg \n\nand 100 mg) of volunteer per dose and by the variability inter-subject. \n\nThe mean lodenafil pharmacokinetic parameters for tmax (1.6\u00b10.4 hr) was similar to the \n\nPDE5 (sildenafil 1 h, tadalafil 1.8 h, vardenafil 0.75 h, udenafil 1 h, and avanafil 0.33 h). The \n\nmean lodenafil pharmacokinetic parameters for t1/2 (3.3h) were similar to the sildenafil and \n\nvardenafil  (sildenafil 2.76 h, vardenafil 2.63 h, avanafil 5.36 h, udenafil 11 h and tadalafil \n\n21.1 h) [6]-[10]. \n\n\n\n \n\n 43  \n \n\nNo serious adverse events were observed, and none of the subjects discontinued the \n\nstudy because of lack of tolerance. As shown in Tables 4 and 5, the AMAP measurements and \n\nclinical tests revealed no significant alteration even at a higher dose. The lodenafil carbonate \n\npresented good tolerance and safety for healthy male volunteers in phase I study. The \n\nrecommended dose of 80 mg was used in following trials and it is the commercial formulation \n\ndose marketed in Brazil. \n\n \n\nAcknowledgements: The Phase I trial was sponsored by Crist\u00e1lia Produtos Qu\u00edmicos e \n\nFarmac\u00eauticos Ltda, Itapira, Brazil. AcademicEnglishSolutions.com revised the English. \n\nReferences:  \n\n[1] Toque HA, Teixeira CE, Lorenzetti R, Okuyama CE, Antunes E, De \n\nNucci G. Pharmacological characterization of a novel phosphodiesterase type 5 \n\n(PDE5) inhibitor lodenafil carbonate on human and rabbit corpus cavernosum. Eur J \n\nPharmacol. 2008;591(1-3):189-95.  \n\n[2] Silva AC, Toffoletto O, Lucio LA, Santos PF, Afiune JB, Massud Filho \n\nJ, Tufik S. [Cardiovascular repercussion of lodenafil carbonate, a new PDE5 inhibitor, \n\nwith and without alcohol consumption]. Arq Bras Cardiol. 2010;94(2):150-6. \n\n[3] Glina S, Toscano I, Gomatzky C, de G\u00f3es PM, J\u00fanior AN, Claro JF, \n\nPagani E. Efficacy and tolerability of lodenafil carbonate for oral therapy in erectile \n\ndysfunction: a phase II clinical trial. J Sex Med. 2009;6(2):553-7.  \n\n[4] Glina S, Fonseca GN, Bertero EB, Dami\u00e3o R, Rocha LC, Jardim CR, \n\nCairoli CE, Teloken C, Torres LO, Faria GE, da Silva MB, Pagani E. Efficacy and \n\ntolerability of lodenafil carbonate for oral therapy of erectile dysfunction: a phase III \n\nclinical trial. J Sex Med. 2010;7(5):1928-36.  \n\n\n\n \n\n 44  \n \n\n[5] Di\u00e1rio Oficial da Uni\u00e3o \u2013 DOU, \n\nhttp://www.in.gov.br/imprensa/visualiza/index.jsp?jornal=1010&amp;pagina=22&amp;data=22/\n\n10/2007. \n\n[6] Stavros F, Kramer WG, Wilkins MR. The effects of sitaxentan on \n\nsildenafil pharmacokinetics and pharmacodynamics in healthy subjects. Br J Clin \n\nPharmacol. 2010 Jan;69(1):23-6. \n\n[7] Garraffo R, Lavrut T, Ferrando S, Durant J, Rouyrre N, MacGregor TR, \n\nSabo JP, Dellamonica P. Effect of tipranavir/ritonavir combination on the \n\npharmacokinetics of tadalafil in healthy volunteers. J Clin Pharmacol. 2011 \n\nJul;51(7):1071-8.  \n\n[8] Berry B, Altman P, Rowe J, Vaisman J. Comparison of \n\nPharmacokinetics of Vardenafil Administered Using an Ultrasonic Nebulizer for \n\nInhalation vs. a Single 10-mg Oral Tablet. J Sex Med. 2009 Jul 28.  \n\n[9] Zhao C, Kim SW, Yang DY, Kim JJ, Park NC, Lee SW, Paick JS, Ahn \n\nTY, Min KS, Park K, Park JK. Eur Urol. Efficacy and safety of once-daily dosing of \n\nudenafil in the treatment of erectile dysfunction: results of a multicenter, randomized, \n\ndouble-blind, placebo-controlled trial. 2011 Aug;60(2):380-7. \n\n[10] Jung J, Choi S, Cho SH, Ghim JL, Hwang A, Kim U, Kim BS, Koguchi \n\nA, Miyoshi S, Okabe H, Bae KS, Lim HS. Tolerability and pharmacokinetics of \n\navanafil, a phosphodiesterase type 5 inhibitor: a single- and multiple-dose, double-\n\nblind, randomized, placebo-controlled, dose-escalation study in healthy Korean male \n\nvolunteers. Clin Ther. 2010 Jun;32(6):1178-87. \n\n\n\n \n\n 45  \n \n\n[11] Report of the Dietary Guidelines Advisory Committee on the Dietary \n\nGuidelines for Americans, 2000, \n\nhttp://www.health.gov/dietaryguidelines/dgac/pdf/dgac_ful.pdf \n\n[12] Limin M, Johnsen N, Hellstrom WJ. Avanafil, a new rapid-onset \n\nphosphodiesterase 5 inhibitor for the treatment of erectile dysfunction. Expert Opin \n\nInvestig Drugs. 2010;19(11):1427-37. \n\n[13] De Nucci G. Estudo cl\u00ednico fase I do carbonato de lodenafila em \n\nvolunt\u00e1rios sadios do sexo masculino. Int Braz J Urol. 2007; 33 (Suppl 2): 148. \n\n \n\n \n\n \n\n \n\n \n\n \n\n \n\n \n\n \n\n \n\n \n\n \n\n \n\n\n\n \n\n 46  \n \n\nTable 1: Treatment scheme with lodenafil in 1 mg, 2 mg, 3 mg, 5 mg, 8 mg, 10 mg, 20 mg, \n\n30 mg, 50 mg, 80 mg and 100 mg in healthy male volunteers. \n\nVolunteer 1 mg 2 mg 3 mg 5 mg 8 mg 10 mg 20 mg 30 mg 50 mg 80 mg 100 mg \nI x x x         \nII x x x         \nIII x x x         \nIV  x x x        \nV  x x x        \nVI  x x x        \nVII   x x x       \nVIII   x x x       \nIX   x x x       \nX    x x x      \nXI    x x x      \nXII    x x x      \nXIII     x x x     \nXIV     x x x     \nXV     x x x     \nXVI      x x x    \nXVII      x x x    \nXVIII      x x x    \nXIX       x x x   \nXX       x x x   \nXXI       x x x   \nXXII        x x x  \nXXIII        x x x  \nXXIV        x x x  \nXXV         x x x \nXXVI         x x x \nXXVII         x x x \nXXVIII          x x \nXXIX          x x \nXXX          x x \nXXXI           x \nXXXII           x \nXXXIII           x \n\n \n\n \n\n \n\n \n\n\n\n \n\n 47  \n \n\nTable 2: Accuracy and precision data for lodenafil carbonate and lodenafil from the pre-study \nvalidation in human plasma. \n \n\nLodenafil carbonate \n\nNominal \nconcentration \n\n(in ng/mL) \n\nIntra-batch mean \n(in ng/mL) \n\nIntra-\nbatch \n\nprecision \n(CV %) \n\nIntra-\nbatch \n\naccuracy \n(%) \n\nInter-\nbatch \n\nmean (in \nng/mL) \n\nInter-\nbatch \n\nprecision \n(CV%) \n\nInter-\nbatch \n\naccuracy \n(%) \n\n0.5 0.55 12.55% 109.29% \n0.52 15.38% 103.42% 0.5 0.47 14.16% 93.70% \n\n0.5 0.53 17.01% 105.89% \n3 3.1 3.61% 102.42% \n\n3.2 8.70% 105.17% 3 3.1 4.01% 104.50% \n3 3.3 14.98% 109.72% \n\n30 32.8 4.25% 109.25% \n33.3 9.32% 110.89% 30 33.9 10.23% 113.08% \n\n30 33.1 12.38% 110.33% \n180 187.3 2.33% 104.03% \n\n189.5 6.16% 105.30% 180 191.4 3.11% 106.32% \n180 190.0 10.30% 105.56% \n\n1800 1923 6.06% 106.81% \n1894 5.91% 105.23% 1800 1935 5.39% 107.50% \n\n1800 1825 5.03% 101.39% \nLodenafil \n\nNominal \nconcentration \n\n(in ng/mL) \n\nIntra-batch mean \n(in ng/mL) \n\nIntra-\nbatch \n\nprecision \n(CV %) \n\nIntra-\nbatch \n\naccuracy \n(%) \n\nInter-\nbatch \n\nmean (in \nng/mL) \n\nInter-\nbatch \n\nprecision \n(CV%) \n\nInter-\nbatch \n\naccuracy \n(%) \n\n0.5 0.54 19.67% 107.13% \n0.51 16.39% 101.02% 0.5 0.48 19.02% 96.37% \n\n0.5 0.50 7.95% 100.33% \n3 2.8 11.33% 92.29% \n\n2.7 9.66% 90.26% 3 2.7 7.36% 89.75% \n3 2.7 10.79% 88.52% \n\n30 28.7 5.25% 95.63% \n27.6 8.42% 91.97% 30 27.8 10.50% 92.75% \n\n30 25.8 5.18% 86.06% \n180 163.5 5.48% 90.83% \n\n157.7 8.69% 87.59% 180 157.9 6.61% 87.71% \n180 151.6 12.27% 84.24% \n\n1800 1604 3.60% 89.10% \n1623 5.32% 90.14% 1800 1685 4.41% 93.61% \n\n1800 1579 5.88% 87.71% \n \n\nLegends: CV = coefficient of variation; \n \n\n \n\n\n\n \n\n 48  \n \n\nTable 3: Mean pharmacokinetic parameters obtained from volunteers after administration of \nlodenafil carbonate formulation (1 mg, 2 mg, 3 mg, 5 mg, 8 mg, 10 mg, 20 mg, 30 mg, 50 mg, \n80 mg and 100 mg) in 33 healthy volunteers. \n \n\nDose (mg) 1.00 2.00 3.00 5.00 \n\nVariable Mean SD Mean SD Mean SD Mean SD \n\nAUC Extrap (%) 65.65 36.92 32.61 23.63 31.39 18.59 30.15 23.04 \n\nAUCinf (hr*ng/mL) 15.99 13.19 7.02 3.65 12.82 5.26 12.13 6.02 \n\nAUClast (hr*ng/mL) 2.07 1.98 3.67 2.37 8.11 3.84 6.45 5.89 \n\nCmax (ng/mL) 1.76 1.61 2.87 1.67 2.77 0.42 3.71 2.36 \n\ntmax (hr) 0.75 0.00 1.17 0.49 2.06 2.46 2.22 2.06 \n\nKe (1/hr) 0.17* 0.20 0.47 0.25 0.30 0.29 0.33 0.20 \n\nt1/2 (hr) 14.62* 17.54 2.37 2.38 4.02 2.25 3.33 2.61 \n\nVd (L) 1009.00* 750.00 925.00 463.00 1266.00 472.00 1951.00 1299.00 \n\nCl (L/hr) 95.00* 78.00 355.00 189.00 283.00 147.00 497.00 228.00 \n\nDose (mg) 8.00 10.00 20.00 30.00 \n\nVariable Mean SD Mean SD Mean SD Mean SD \n\nAUC Extrap (%) 31.08 23.41 24.27 24.18 6.75 4.08 14.82 18.71 \n\nAUCinf (hr*ng/mL) 22.62 15.73 29.69 24.85 55.53 39.71 86.69 85.97 \n\nAUClast (hr*ng/mL) 17.54 16.34 24.99 24.45 46.18 39.87 82.40 86.41 \n\nCmax (ng/mL) 8.08 6.92 10.92 12.20 19.21 13.74 24.39 19.37 \n\ntmax (hr) 2.11 1.29 1.38 0.50 1.86 1.99 1.44 0.92 \n\nKe (1/hr) 0.35 0.20 0.41 0.35 0.42 0.30 0.25 0.13 \n\nt1/2 (hr) 2.97 2.23 2.66 1.92 2.59 1.75 3.78 2.61 \n\nVd (L) 2348.00 1908.00 2435.00 2435.00 1477.00 789.00 6037.00 7740.00 \n\nCl (L/hr) 613.00 553.00 796.00 821.00 490.00 257.00 1007.00 1175.00 \n\nDose (mg) 50.00 80.00 100.00 Mean \n\nVariable Mean SD Mean SD Mean SD Mean SD \n\nAUC Extrap (%) 5.90 4.83 21.07 29.71 5.23 3.53 - - \n\nAUCinf (hr*ng/mL) 65.91 51.90 49.16 39.69 89.72 73.32 - - \n\nAUClast (hr*ng/mL) 63.37 51.36 42.80 41.95 86.66 73.25 - - \n\nCmax (ng/mL) 24.09 15.39 17.62 15.40 37.27 29.02 - - \n\ntmax (hr) 1.67 1.04 1.86 1.08 1.42 1.02 1.6 0.4 \n\nKe (1/hr) 0.32 0.12 0.25 0.16 0.33 0.16 0.3 0.1 \n\nt1/2 (hr) 2.59 1.25 5.93 9.12 2.56 1.24 3.3 1.1 \n\nVd (L) 4137.00 2902.00 22971.00 28532.00 5581.00 3189.00 4913 6590.5 \n\nCl (L/hr) 1361.00 1189.00 3274.00 2955.00 1784.00 1120.00 1046 914.7 \n \n\nLegends: Ke = elimination rate constant; t1/2 = half-life; Cmax = maximum plasma concentration; tmax \n= time to the maximum plasma concentration, AUClast - area under curve from time zero to the last \n\ndetectable concentration AUCinf = extrapolation of area to infinity, AUC Extrap = % extrapolation of \narea to infinity; CL = clearance; VD = volume of distribution; Clast = last detectable concentration, \n\ntlast = time of last detectable concentration, * = excluded of descriptive statistic. \n \n\n\n\n \n\n 49  \n \n\nTable 4: Laboratory tests in healthy male volunteers after administration of lodenafil \ncarbonate. \n\n \n\nType Unit Normal range \n\nPre-study Pos-study \n\nMean SD Min Max Mean SD Min Max \n\nH\nem\n\nat\nol\n\nog\nic\n\nal\n \n\nHemoglobin g% 13.5 - 17.5 15.4 0.8 14.1 17.2 14.6 0.8 12.9 16.8 \nHematocrit % 39 - 50 44.7 1.9 42.2 49.4 42.9 2.1 40.1 47.7 \n\nRed Blood Count 106/mm3  4.3 - 5.7 5.2 0.6 4.7 8.0 4.8 0.2 4.5 5.2 \nVCM Micra3  81 - 95 84.4 17.1 5.2 93.6 89.0 2.4 85.3 93.3 \n\nHbCM pg 26 - 34 29.6 3.4 14.9 33.4 30.3 1.3 27.4 32.9 \nWhite Blood Count 103/mm3 3500 - 10500 6.4 1.3 3.7 8.4 6.9 1.7 4.2 10.6 \nBand Neutrophils % ? 5 1.7 1.0 1.0 5.0 1.7 0.7 1.0 3.0 \n\nSegmented  % 48 - 76 55.0 8.6 36.1 66.7 54.6 8.7 32.1 65.8 \nLymphocytes % 25 - 30 31.9 8.6 18.4 50.3 31.8 7.9 21.9 51.5 \n\nMonocytes % 1 - 9 7.7 1.7 4.7 10.3 7.8 2.2 4.8 12.0 \nBasophils % 0 - 1 0.6 0.4 0.0 1.8 0.5 0.3 0.0 1.0 \n\nEosinophils % 1 - 5  3.8 2.8 0.6 10.7 4.0 2.5 1.0 9.9 \nPlatelet Count - 150 \u2013 400 238.5 50.0 153.0 363.0 247.3 44.4 162.0 328.0 \n\nB\nio\n\nch\nem\n\nic\nal\n\n \n\nTotal Cholesterol  mg/dL  ? 239 167.3 30.9 112.0 239.0 165.5 42.0 22.0 248.0 \nTriglycerids mg/dL ? 150 102.4 44.5 45.0 191.0 99.6 54.1 24.0 303.0 \n\nTotal Proteins g/dL 6 - 8 7.8 0.3 7.3 8.4 7.7 0.3 7.2 8.3 \nAlbumin g/dL 3.5 - 5.5 4.7 0.2 4.4 5.0 4.6 0.2 4.2 5.1 \nUric Acid mg/dL 2.5 \u2013 7.0 5.5 1.5 3.1 9.0 5.4 1.3 3.0 8.8 \n\nTotal Bilirubins mg/dL 0 - 1.1 0.8 0.5 0.4 2.6 0.6 0.4 0.0 1.4 \nAlkaline Phosphatase U/L 27 - 100 76.2 18.9 49.0 115.0 67.6 24.5 0.8 116.0 \n\ngT U/L   24.1 11.9 8.0 63.0 23.8 11.2 5.2 47.0 \nSGOT  (AST) U/L ? 43 21.9 5.5 15.0 42.0 20.2 4.1 12.0 34.0 \nSGPT  (ALT) U/L ? 43 23.2 11.0 13.0 64.0 23.1 9.7 10.0 53.0 \n\nUrea mg/dL 10 - 50 26.6 5.4 14.4 36.7 29.1 5.5 17.2 38.0 \nCreatinine mg/dL 0.4 - 1.3 1.1 0.8 0.8 4.7 1.1 0.9 0.7 4.5 \n\nFasting Blood Glucose mg/dL 60 - 100 87.2 8.1 74.0 108.0 87.9 6.9 74.0 101.0 \n\nU\nri\n\nn\ne \n\nSpecific Gravity - 1.015 - 1.028 1019.3 5.8 1008.0 1029.0 1019.6 6.1 1006.0 1032.0 \npH - 5.5 - 6.5 6.2 0.6 5.5 7.0 6.2 0.4 5.5 6.5 \n\nWBC /mL ? 10000 7124.2 16901.9 300.0 97000.0 3277.0 1924.3 1000.0 9400.0 \nRBC /mL ? 5000 4150.0 4784.6 300.0 19430.0 2900.0 3924.6 100.0 22900.0 \n\n \n\n \n\n \n\n \n\n \n\n \n\n \n\n \n\n\n\n \n\n 50  \n \n\nTable 5: Mean sitting systolic and diastolic blood pressures and mean heart rates after \n\nlodenafil carbonate administration. \n\nTime \n\nMean diastolic blood \n\npressures \n\nMean systolic blood \n\npressures Mean heart rate \n\nMean SD Min Max Mean SD Min Max Mean SD Min Max \n\n0 71 7 56 89 113 8 91 132 63 7 41 86 \n\n1 70 7 54 93 113 8 86 134 59 7 42 77 \n\n2 72 8 52 96 114 8 88 134 61 8 43 85 \n\n3 69 9 45 99 115 8 88 145 65 10 45 100 \n\n4 68 9 41 93 115 10 95 138 66 10 43 107 \n\n5 71 10 44 97 118 9 89 143 72 11 48 107 \n\n6 65 9 40 89 113 10 77 135 67 8 49 85 \n\n7 66 10 40 96 112 9 85 133 68 10 46 99 \n\n8 67 9 40 93 112 10 90 135 66 10 46 92 \n\n9 65 11 43 86 112 16 90 140 65 12 46 97 \n\n10 66 9 43 88 112 11 84 143 68 10 48 92 \n\n11 68 11 44 90 114 10 86 138 65 10 48 92 \n\n12 74 10 50 98 117 11 94 149 70 14 47 111 \n\n13 70 11 44 95 117 10 93 146 69 11 47 104 \n\n14 69 10 44 89 116 10 82 143 70 10 49 102 \n\n15 64 10 46 94 112 11 91 142 66 10 46 99 \n\n16 65 8 46 84 113 10 83 144 67 11 45 115 \n\n17 62 9 44 80 110 10 84 135 64 10 44 89 \n\n18 63 10 41 89 110 11 86 136 62 11 42 98 \n\n19 63 8 43 81 108 8 87 127 62 13 42 138 \n\n20 65 8 45 88 109 10 88 133 62 10 42 87 \n\n21 62 10 43 91 105 11 83 142 60 10 46 105 \n\n22 62 10 40 84 105 12 79 132 59 9 41 82 \n\n23 63 11 42 91 106 11 74 127 61 11 39 98 \n\n24 73 8 54 91 116 7 98 132 70 9 49 91 \n\n \n\n\n\n \n\n 51  \n \n\nFigure 1: The mean lodenafil plasma concentrations vs. time profiles after a single oral dose (1 mg, 2 mg, 3 mg, 5 mg, 8 mg, \n\n10 mg, 20 mg, 30 mg, 50 mg, 80 mg, 100 mg) tablet formulation of lodenafil carbonate in male volunteers. \n\n  \n\n  \n\n  \n\n  \n\n  \n\n \n\n  Dose - 100 mg\n\n0 2 4 6 8 10 12 14 16 18 20 22 24\n\n0\n\n10\n\n20\n\n30\n\n40\n\nTime ( h)\n\nM\ne\n\nan\n C\n\no\nn\n\nc\nen\n\ntr\na\n\nti\no\n\nn\n(n\n\ng\n/m\n\nL\n)\n\n\n\n \n\n 52  \n \n\nFigure 2: Mean sitting systolic and diastolic blood pressures and sitting heart rates after \n\nlodenafil carbonate administration. \n\nEffect on blood pressure of lodenafil carbonate\n\n0 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21 22 23 24\n\n40\n\n50\n\n60\n\n70\n\n80\n\n90\n\n100\n\n110\n\n120\n\n130\n\n140\n\nDiastolic Blood Pressure Systolic Blood Pressure\n\nTime (h)\n\nm\nm\n\nH\ng\n\n \n\nMean heart rate\n\n0 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21 22 23 24\n\n40\n\n50\n\n60\n\n70\n\n80\n\n90\n\n100\n\nTime (h)\n\nM\ne\nan\n\n h\ne\nar\n\nt \nra\n\nte\n/m\n\nin\n\n \n\n \n\n\n\n \n\n 53  \n \n\n3. Discuss\u00e3o \n\n \n\nA cromatografia l\u00edquida de alto desempenho (HPLC), acoplado com espectrometria de \n\nmassa (LC-MS-MS) tem sido utilizada para quantifica\u00e7\u00e3o de carbonato de lodenafila e ou \n\nlodenafila no plasma humano e de animais. No entanto, nenhum m\u00e9todo de valida\u00e7\u00e3o \n\ncompleto foi publicado anteriormente para quantifica\u00e7\u00e3o de lodenafila e carbonato de \n\nlodenafila. O nosso m\u00e9todo emprega sildenafila como padr\u00e3o interno em vez de teofilina, \n\ntendo um tempo de reten\u00e7\u00e3o mais curto de 1,1 min. para o carbonato de lodenafila e 0,8 min. \n\npara lodenafila. O limite de quantifica\u00e7\u00e3o (0,5 ng / ml) foi adequado para avalia\u00e7\u00e3o de \n\nfarmacocin\u00e9tica de carbonato lodenafila e lodenafila. \n\nOs resultados obtidos ap\u00f3s a administra\u00e7\u00e3o oral de carbonato de lodenafila em \n\nvolunt\u00e1rios saud\u00e1veis do sexo masculino mostraram que o carbonato de lodenafila atua como \n\num pr\u00f3-droga quando administrado por via oral, uma vez que nenhuma concentra\u00e7\u00e3o \n\nquantific\u00e1vel de carbonato de lodefanila foi detectada na circula\u00e7\u00e3o sist\u00eamica. Resultados \n\nsemelhantes foram observados em beagles machos ap\u00f3s a administra\u00e7\u00e3o oral de carbonato \n\nlodenafila. \n\nO evento adverso dis\u00faria n\u00e3o foi considerado como relacionado \u00e0 terapia uma vez que \n\nocorreu 74 horas ap\u00f3s a administra\u00e7\u00e3o da droga (20 mg) e a m\u00e9dia do tempo de meia-vida \n\npara lodenafila \u00e9 de 3,3 horas. Foi avaliado como n\u00e3o grave, pois ocorreu recupera\u00e7\u00e3o \n\nespont\u00e2nea e o volunt\u00e1rio apenas o relatou na avalia\u00e7\u00e3o m\u00e9dica final. \n\nAp\u00f3s a administra\u00e7\u00e3o oral de comprimidos de carbonato de lodenafila 80 mg, para os \n\nvolunt\u00e1rios, o tmax (1.6h) e t1/2 (3.3h) foram similares ao descrito na literatura  (tmax: 1.2 -\n\n1.5h; t1/2: 2.4 \u2013 3h). Os valores de Cmax (17.62 ng/mL) e a AUC (42.80 hr*ng/mL) foram \n\ndiferentes daqueles relatados na literatura (Cmax 158 ng/mL; AUC 528 hr*ng/mL) para a \n\n\n\n \n\n 54  \n \n\nformula\u00e7\u00e3o de comprimidos de carbonato de lodenafila (dose 160 mg; dois comprimidos de \n\n80 mg). \n\nOs par\u00e2metros farmacocin\u00e9ticos calculados para 1 mg n\u00e3o s\u00e3o confi\u00e1veis devido \u00e0 baixa \n\nconcentra\u00e7\u00e3o de lodenafila no plasma ap\u00f3s uma dose de 1 mg. A maior diferen\u00e7a para  t1/2, \n\nCl e Vd ,ao longo do intervalo de dose, pode ser explicada pelo baixo n\u00famero de volunt\u00e1rios \n\npor dose  (n=3 para 1 mg; n=6 para 2mg e n=9 entre 3 mg and 100 mg)  e pela variabilidade \n\ninter-sujeitos. \n\nAs m\u00e9dias dos par\u00e2metros farmacocin\u00e9ticos de lodenafila para Tmax (1,6 \u00b1 0,4 hr) foi \n\nsemelhante aos PDE5 (sildenafila 1 h, tadalafila1, 8 h, vardenafila 0,75 h, udenafila 1 h, e \n\navanafila 0,33 h). A m\u00e9dia dos par\u00e2metros farmacocin\u00e9ticos de lodenafila de t1 / 2 (3.3 h) foi \n\nsimilar \u00e0 sildenafila e vardenafila (sildenafila 2,76 h, vardenafila 2,63 h, avanafila 5,36 h, \n\nudenafila 11 h e tadalafila 21,1 h). \n\n \n\n \n\n \n\n \n\n \n\n \n\n \n\n \n\n \n\n \n\n \n\n \n\n\n\n \n\n 55  \n \n\n4. Conclus\u00e3o \n\n \n\nN\u00e3o foi observado evento adverso grave e nenhum dos volunt\u00e1rios descontinuou o \n\nestudo por falta tolerabilidade. \n\nO Carbonato de Lodenafila apresenta boa tolerabilidade e seguran\u00e7a no estudo fase I \n\ncom volunt\u00e1rios saud\u00e1veis. \n\nA dose recomendada de 80 mg foi usada em estudos cl\u00ednicos posteriores a este e \u00e9 a \n\nformula\u00e7\u00e3o comercializada no Brasil. \n\n \n\n \n\n \n\n \n\n \n\n \n\n \n\n \n\n \n\n \n\n \n\n \n\n \n\n \n\n \n\n\n\n \n\n 56  \n \n\n5. Refer\u00eancias bibliogr\u00e1ficas \n\n \n1. Morgentaler A. Male impotence. Lancet. 1999;354(9191):1713-8. \n\n2. Laumann EO, Paik A, Rosen RC. Sexual dysfunction in the United States: prevalence and \npredictors. JAMA. 1999;281(6):537-44. \n\n3. Jungwirth A, Giwercman A, Tournaye H, Diemer T, Kopa Z, Dohle G,et al.  European \nAssociation of Urology guidelines on Male Infertility: the 2012 update. Eur Urol. \n2012;62(2):324-32. \n\n4. Kubin M, Wagner G, Fugl-Meyer AR. Epidemiology of erectile dysfunction. Int J Impot \nRes. 2003;15(1):63-71. \n\n5. Moreira ED Jr, Lbo CF, Diament A, Nicolosi A, Glasser DB.  Incidence of erectile \ndysfunction in men 40 to 69 years old: results from a population-based cohort study in Brazil. \nUrology. 2003;61(2):431-6. \n\n6. Abdo C, Oliveira J\u00fanior  WM, Scanavino MT, Martins Gi. Disfun\u00e7\u00e3o er\u00e9til: resultados do \nestudo da vida sexual do brasileiro. Rev Assoc Med Bras. 1992;52(6):424-9. \n\n7. Fazio L, Brock G. Erectile dysfunction: management update. CMAJ. 2004;170(9):1429-37. \n\n8. Qiu Y, Kraft P, Lombardi E, Clancy J. Rabbit corpus cavernosum smooth muscle shows a \ndifferent phosphodiesterase profile than human corpus cavernosum. J Urol. 2000;164(3 Pt \n1):882-6. \n\n9.  Corbin JD. Mechanisms of action of PDE5 inhibition in erectile dysfunction. Int J Impot \nRes. 2004;16 Suppl. 1:S4-7.  \n\n10. Aversa A. Systemic and metabolic effects of PDE5-inhibitor drugs. World J Diabetes. \n2010;1(1):3-7.  \n\n11. Solomon H, Man JW, Jackson G. Erectile dysfunction and the cardiovascular patient: \nendothelial dysfunction is the common denominator. Heart. 2003;89(3):251-3. \n\n12. Selvin E, Burnett AL, Platz EA. Prevalence and risk factors for erectile dysfunction in the \nUS. Am J Med. 2007;120(2):151. \n\n13. Hatzimouratidis K, Amar E, Eardley I, Giuliano F, Hatzichristou D, Montorsi F, et al. \nGuidelines on male sexual dysfunction: erectile dysfunction and premature ejaculation. Eur \nUrol. 2010;57(5):804-14. \n\n14. Santos Pechorro P, Martins Calvinho A, Monteiro Pereira  N, Xavier Vieira R.  Valida\u00e7\u00e3o \nde uma vers\u00e3o portuguesa do \u00cdndice Internacional de Fun\u00e7\u00e3o Er\u00e9ctil-5 (IIEF-5).  Rev Int \nAndrol. 2011;9(1):3-9.  \n\n\n\n \n\n 57  \n \n\n15. Simopoulos EF, Trinidad AC. Male erectile dysfunction: integrating psychopharmacology \nand psychotherapy. Gen Hosp Psychiatry. 2013;35(1):33-8. \n\n16. Limin M, Johnsen N, Hellstrom WJ. Avanafil, a new rapid-onset phosphodiesterase 5 \ninhibitor for the treatment of erectile dysfunction. Expert Opin Investig Drugs. \n2010;19(11):1427-37.  \n\n17. Albersen M, Shindel AW, Mwamukonda KB, Lue TF. The future is today: emerging \ndrugs for the treatment of erectile dysfunction. Expert Opin Emerg Drugs. 2010;15(3):467-80. \n\n18. Vlachopoulos C, Ioakeimidis N, Rokkas K, Stefanadis C. Cardiovascular effects of \nphosphodiesterase type 5 inhibitors. J Sex Med. 2009;6(3):658-74.  \n\n19. Hackett G, Kell P, Ralph D, Dean J, Price D, Speakman M, et al. British Society for \nSexual Medicine guidelines on the management of erectile dysfunction. J Sex Med. \n2008;5(8):1841-65. \n\n20. Eardley I. Oral therapy for erectile dysfunction. Arch Esp Urol. 2010;63(8):703-14. \n\n21. DiMasi JA, Hansen RW, Grabowski HG. The price of innovation: new estimates of drug \ndevelopment costs. J Health Econ. 2003;22(2):151-85. \n\n22. DiMasi JA, Hansen RW, Grabowski HG, Lasagna L. Research and development costs for \nnew drugs by therapeutic category. A study of the US pharmaceutical industry.  \nPharmacoeconomics. 1995;7(2):152-69. \n\n23. Tironi LF, Cruz BDO. Inova\u00e7\u00e3o Incremental ou radical: h\u00e1 motivos para diferenciar? Uma \nabordagem com dados da PINTEC. 2008; texto para discuss\u00e3o n\u00ba 1360. \n\n24. Kola I, Landis J. Can the pharmaceutical industry reduce attrition rates? Nat Rev Drug \nDiscov. 2004;3(8):711-5. \n\n25. Tidd J, Trewhella MJ. Organizational and technological antecedents for knowledge \nacquisition and learning. R&amp;D Management. 1997; 27(4),359-75. \n\n26. Nat\u00e9rcia F. Parcerias e inova\u00e7\u00e3o impulsionam setor farmac\u00eautico. Inova\u00e7\u00e3o Unicamp. \n2005; 1(3): 32-7. \n\n27. Santos M. Estrat\u00e9gias tecnol\u00f3gicas em transforma\u00e7\u00e3o: um estudo da ind\u00fastria \nfarmac\u00eautica brasileira. Disserta\u00e7\u00e3o (Mestrado em Engenharia de Produ\u00e7\u00e3o). Universidade \nFederal de S\u00e3o Carlos, S\u00e3o Carlos. 2010. 190 p.  \n\n28. Organiza\u00e7\u00e3o Pan-Americana da Sa\u00fade, Organiza\u00e7\u00e3o Mundial da Sa\u00fade, Rede Pan-\nAmericana para Harmoniza\u00e7\u00e3o da Regulamenta\u00e7\u00e3o Farmac\u00eautica. Boas Pr\u00e1ticas Cl\u00ednicas: \nDocumento das Am\u00e9ricas. Bras\u00edlia: Opas/OMS; 2005. \n\n29. Quental C, Salles Filho S. Ensaios cl\u00ednicos: capacita\u00e7\u00e3o nacional para avalia\u00e7\u00e3o de \nmedicamentos e vacinas. Rev  Bras Epidemiol. 2006;9(4): 408-24. \n\n\n\n \n\n 58  \n \n\n30. Woolley PV, Schein PS. Clinical pharmacology and phase I trial design. Methods in \nCancer Research. 1979;17: 177-98. \n\n31. Food and Drug Administration, Center for Drug Evaluation and Research. Guidance for \nindustry - Estimating the maximum safe starting dose in initial clinical trials for therapeutics \nin adult healthy volunteers. US Department of Health and Human Services, 2005. \n\n  \n\n32. Ag\u00eancia Nacional de Vigil\u00e2ncia Sanit\u00e1ria. Guia para a condu\u00e7\u00e3o de estudos n\u00e3o cl\u00ednicos \nde seguran\u00e7a necess\u00e1rios ao desenvolvimento de medicamentos.  Dispon\u00edvel em: \nhttp://portal.anvisa.gov.br/wps/wcm/connect/e0f1d9004e6248049d5fddd762e8a5ec/Guia+de+\nEstudos+N%C3%A3o+Cl%C3%ADnicos+-+vers%C3%A3o+2.pdf?MOD=AJPERES. \nAcesso em: 15.01.2013.  \n\n33. Schneiderman MA. Mouse to man: statistical problems in bringing a drug to clinical trial. \nIn Proceedings of the fifth Berkeley symposium on mathematical statistics and probability. \n1967; 4: 855-66. \n\n34. Pereira LDC, Ferreira M V. Sequ\u00eancia de Fibonacci: hist\u00f3ria, propriedades e rela\u00e7\u00f5es com \na raz\u00e3o \u00e1urea. Disc. Scientia. 2008,9(1): 67-81. \n\n35. Trotti A, Colevas AD, Setser A, Rusch V, Jaques D, Budach V, et al. CTCAE v3.0: \ndevelopment of a comprehensive grading system for the adverse effects of cancer treatment. \nSemin Radiat Oncol. 2003;13(3):176-81. \n\n36. Mahmood I, Green MD, Fisher JE. Selection of the first-time dose in humans: comparison \nof different approaches based on interspecies scaling of clearance. J Clin Pharmacol. \n2003;43(7):692-7. \n\n37. Vijayaraghavan R, Kumar GR. Impact of phase zero trials (micro-dosing) in clinical trial \nresearch. Int J Appl Biol Pharm Tech. 2010;2:486-90. \n\n38. Flores Toque HA, Priviero FB, Teixeira CE, Perissutti E, Fiorino F, Severino B, et al. \nSynthesis and pharmacological evaluations of sildenafil analogues for treatment of erectile \ndysfunction. J Med Chem. 2008;51(9):2807-15.  \n\n39. De Nucci G, Lorenzetti R, Okuyama C E, Baracat JS, Donato JL, Antunes E, et al. \nPharmacological characterization of the novel phosphodiesterase type 5 (PDE5) inhibitor \nlodenafil carbonate on human and rabbit corpus cavernosum. BMC Pharmacology.2008; \n7(Suppl. 1), 13. \n\n40. Toque HA, Teixeira CE, Lorenzetti R, Okuyama CE, Antunes E, De Nucci G. \nPharmacological characterization of a novel phosphodiesterase type 5 (PDE5) inhibitor \nlodenafil carbonate on human and rabbit corpus cavernosum. Eur J Pharmacol. 2008;591(1-\n3):189-95.  \n\n  \n\n\n\nadriana.yamaguchi\nTexto digitado\n\nadriana.yamaguchi\nTexto digitado\n\nadriana.yamaguchi\nTexto digitado\n\nadriana.yamaguchi\nTexto digitado\n\nadriana.yamaguchi\nTexto digitado\n\nadriana.yamaguchi\nTexto digitado\n\nadriana.yamaguchi\nTexto digitado\n\nadriana.yamaguchi\nTexto digitado\n\nadriana.yamaguchi\nTexto digitado\n\nadriana.yamaguchi\nTexto digitado\n\nadriana.yamaguchi\nTexto digitado\n\nadriana.yamaguchi\nTexto digitado\n59\n\n\n\n \n\n 60  \n \n\nANEXO II \n\n \n\nDe: J\u00f6rg Feistle [mailto:joerg.feistle@dustri.de]  \n\nEnviada em: segunda-feira, 10 de junho de 2013 03:20 \n\nPara: 'Hilton Oliviera Santos' \n\nCc: 'Gilberto De Nucci' \n\nAssunto: AW: A phase I clinical trial of lodenafil carbonate, a new phosphodiesterase type 5 (PDE5) \n\ninhibitor, in healthy male volunteers. - (Manuscript-ID 201624 - 3) \n\n Dear Doctor Santos Filho, \n\n Thank you for your email. Dustri-Verlag grants permission to include the text of the article \n\n H. Oliveira dos Santos Filho, A. dos Santos Pereira, F. D. Mendes, T. Babad\u00f3pulos, J. O. Ilha, K.M. \nAlkharfy, G.D. Mendes and G. De Nucci: A phase I clinical trial of lodenafil carbonate, a new \nphosphodiesterase type 5 (PDE5) inhibitor, in healthy male volunteers \n\n of our Int. Journal of Clinical Pharmacology and Therapeutics, Vol. 50, no. 12/2012, pp. 896-906, in \nyour thesis, as requested in your letter. \n\n We request to give full credit to the author and publisher, either as a foot note, or as a reference \nwithin the text or both. \n\n Sincerely yours, \n\n  \n\nJoerg Feistle  \nDustri-Verlag Dr. Karl Feistle GmbH &amp; Co. KG  \nBajuwarenring 4  \n82041 Oberhaching, Germany  \nP.O. Box 1351  \n82032 Deisenhofen, Germany  \nPhone +49-89-613861-30  \nFax +49-89-613861-80  \nEmail Joerg.Feistle@dustri.com  \n\nhttp://www.dustri.com, http://www.clinnephrol.com, http://www.clinpharmacol.com  \n\nCourt of Registry: Local Court of Munich, Germany, HRA 81557, CEO: Joerg Feistle, Frank Feistle, Gerhard Feistle  \n\n \n\n \n\n \n\n \n\n \n\n \n\nadriana.yamaguchi\nTexto digitado\n\n\n\n \n\n 61  \n \n\nANEXO III \n\n \n\nEstudo publicado:  \n\nInt J Clin Pharmacol Ther. 2012 Dec;50(12):896-906.  \n\nA Phase I clinical trial of lodenafil carbonate, a new phosphodiesterase Type 5 (PDE5) \ninhibitor, in healthy male volunteers. \n\nMendes GD, dos Santos Filho HO, dos Santos Pereira A, Mendes FD, Ilha JO, Alkharfy \nKM, De Nucci G. \n\nSourceDepartment of Pharmcology, State University of Campinas, Campinas, Brazil. \ngugamendes@terra.com.br \n\nAbstract \n\nLodenafil carbonate is a new phosphodiesterase Type 5 (PDE5) inhibitor used in treatment of \nerectile dysfunction. Objective: The present study was conducted to evaluate the safety, \ntolerability, and pharmacokinetics of lodenafil carbonate after administering ascending (1 - \n100 mg) single oral doses to healthy male volunteers (n = 33). Methods: The study was an \nopen label, dose-escalation, Phase I clinical trial involving the administration of single oral \ndoses of lodenafil carbonate. Lodenafil carbonate was administered sequentially, escalating in \nsingle doses of 1 mg - 100 mg with a washout period of at least 1 week between each dose. \nThe progression to the next dose was allowed after clinical and laboratory exams, Ambulatory \nMonitoring of Arterial Pressure (AMAP) without relevant clinical modifications and adverse \nevents without clinical relevancy. Blood samples were collected at pre-dose, 0.25, 0.5, 0.75, \n1, 1.25, 1.5, 1.75, 2, 2.5, 3, 3.5, 4, 4.5, 5, 6, 7, 8, 10, 12, 14, 16, 20 and 24 h post-dosing. \nPlasma samples for measurement of lodenafil carbonate and lodenafil were analyzed by liquid \nchromatography coupled to tandem mass spectrometry. Results: No serious adverse events \nwere observed, and none of the subjects discontinued the study due to intolerance. The \nAMAP measurements, clinical and laboratory exams and ECG revealed no significant \nchanges even at higher doses. Lodenafil carbonate was not detected in any samples, indicating \nthat it acts as a prodrug. The mean lodenafil pharmacokinetic parameters for tmax and t1/2 \nwere 1.6 ( \u00b1 0.4) h and 3.3 ( \u00b1 1.1) h, respectively. This study demonstrated that lodenafil \ncarbonate was well tolerated and showed a good safety profile in healthy male volunteers. \n\n \n\nPMID:23073140[PubMed - in process] \n\n \n\nadriana.yamaguchi\nTexto digitado\n\n\n\nOriginal\n\u00a92012 Dustri-Verlag Dr. K. Feistle \n\nISSN 0946-1965 \n\nDOI 10.5414/CP201624\ne-pub: October 17, 2012\n\nReceived\nJuly 18, 2011;\naccepted\nMay 28, 2012\n\nCorrespondence to \nGustavo D. Mendes, MD \n415 Jesu?no Marcondes \nMachado Ave., \n13092-320, Campinas \n\u2013 SP, Brazil \ngugamendes@ \nterra.com.br\n\nKey words\nphosphodiesterase Type \n5 (PDE5) inhibitor- phar-\nmacokinetics \u2013 erectile \ndisfunction \u2013 iodenofil \ncarbonate\n\nA Phase I clinical trial of lodenafil carbonate, \na new phosphodiesterase Type 5 (PDE5) \ninhibitor, in healthy male volunteers\nGustavo D. Mendes1,2, Hilton Oliveira dos Santos Filho3, Alberto dos Santos Pereira4, \nFabiana D. Mendes3, Jaime O. Ilha4, Khalid M. Alkharfy5 and Gilberto De Nucci6\n\n1Department of Pharmacology, Faculty of Medical Sciences, State University of \nCampinas (UNICAMP), Campinas/SP, 2Faculty of Odontology, 3Department of \nInternal Medicine, University Camilo Castelo Branco (UNICASTELO), S\u00e3o Paulo, SP, \n4Galeno Research Unit, Campinas, SP, Brazil, 5Department of Clinical Pharmacy, \nCollege of Pharmacy, King Saud University, Riyadh, Saudi Arabia, and \n6Department of Pharmacology, Institute of Biomedical Sciences, University of Sao \nPaulo, S\u00e3o Paulo, Brazil\n\nAbstract. Lodenafil carbonate is a new \nphosphodiesterase Type 5 (PDE5) inhibitor \nused in treatment of erectile dysfunction. \nObjective: The present study was conduct-\ned to evaluate the safety, tolerability, and \npharmacokinetics of lodenafil carbonate \nafter administering ascending (1 \u2013 100 mg) \nsingle oral doses to healthy male volunteers \n(n = 33). Methods: The study was an open-\nlabel, dose-escalation, Phase I clinical trial \ninvolving the administration of single oral \ndoses of lodenafil carbonate. Lodenafil car-\nbonate was administered sequentially, esca-\nlating in single doses of 1 mg \u2013 100 mg with \na washout period of at least 1 week between \neach dose. The progression to the next dose \nwas allowed after clinical and laboratory \nexams, Ambulatory Monitoring of Arterial \nPressure (AMAP) without relevant clinical \nmodifications and adverse events without \nclinical relevancy. Blood samples were col-\nlected at pre-dose, 0.25, 0.5, 0.75, 1, 1.25, \n1.5, 1.75, 2, 2.5, 3, 3.5, 4, 4.5, 5, 6, 7, 8, 10, \n12, 14, 16, 20 and 24 h post-dosing. Plasma \nsamples for measurement of lodenafil car-\nbonate and lodenafil were analyzed by liq-\nuid chromatography coupled to tandem mass \nspectrometry. Results: No serious adverse \nevents were observed, and none of the sub-\njects discontinued the study due to intoler-\nance. The AMAP measurements, clinical \nand laboratory exams and ECG revealed no \nsignificant changes even at higher doses. \nLodenafil carbonate was not detected in any \nsamples, indicating that it acts as a prodrug. \nThe mean lodenafil pharmacokinetic param-\neters for tmax and t1/2 were 1.6 ( \u00b1 0.4) h and \n3.3 ( \u00b1 1.1) h, respectively. This study dem-\nonstrated that lodenafil carbonate was well \ntolerated and showed a good safety profile in \nhealthy male volunteers.\n\nIntroduction\n\nLodenafil carbonate is a new phosphodi-\nesterase Type 5 (PDE5) inhibitor for treat-\nment of erectile dysfunction [1, 2, 3, 4], a \ncommon sexual problem for males over \n40 \u2013 50 years of age. Lodenafil relaxes iso-\nlated human and animal cavernous tissues \nthrough inhibition of cyclic guanosine mo-\nnophosphate hydrolysis [1]. Lodenafil car-\nbonate was approved by Brazilian Sanitary \nSurveillance Agency (ANVISA) in 2007 [5].\n\nThe pharmacokinetic parameters for lode-\nnafil carbonate and lodenafil following oral \nadministration (10 mg) of lodenafil carbon-\nate in male beagle dogs were (mean \u00b1 S.D): \nlodenafil carbonate: 11 \u00b1 14 ng/ml, 23 \u00b1 21 \nng\u00d7h/ml, 2.1 \u00b1 3.0 h, 1.67 \u00b1 1.53 h; lodenafil: \n1,357 \u00b1 961 ng/ml, 9,091 \u00b1 5,526 ng\u00d7h/ml, \n4.3 \u00b1 0.5 h, 4.3 \u00b1 0.5 h for Cmax, AUC, t1/2, \ntmax, respectively [1]. The above results indi-\ncate that lodenafil carbonate acts as a prodrug, \ndelivering lodenafil in vivo as the active moi-\nety, since very small amounts of lodefanil car-\nbonate reached the systemic circulation.\n\nThe tmax for PDE5 inhibitors is between \n0.33 \u2013 1.8 h (sildenafil 1 h, tadalafil 1.8 h, \nvardenafil 0.75 h, udenafil 1 h and avanafil \n0.33 h) and the half-life time for PDE5 in-\nhibitors varies from 2.6 to 21.1 h (sildenafil \n2.76 h, vardenafil 2.63 h, avanafil 5.36 h, \nudenafil 11 h and tadalafil 21.1 h) [6, 7, 8, \n9, 10]. After single oral administrations of \nlodenafil carbonate (160 mg) in healthy male \nvolunteers, lodenafil is rapidly absorbed with \n\nInternational Journal of Clinical Pharmacology and Therapeutics, Vol. 50 \u2013 No. 12/2012 (896-906) \n\n\n\nLodenafil carbonate Phase I study 897\n\npeak of concentration (157 ng/ml) occurring \nat 1.2 h, half-life time of 2.4 h and area under \nthe curve (AUC) of 530 ng\u00d7h/ml [4].\n\nThe present study was conducted to eval-\nuate the safety, tolerability, and pharmaco-\nkinetics of lodenafil carbonate after admin-\nistering ascending (1 \u2013 100 mg) single oral \ndoses in normal healthy male volunteers.\n\nMaterials and methods\n\nClinical protocol\n\nThe following inclusion criteria were \nused: 33 healthy male volunteers, aged be-\ntween 18 and 55 years old and within ? 19 \nand ? 28.75 of the ideal body weight were \nselected for the study [11]. The volunteers \n\nwere selected for the study after having their \nhealth status previously assessed by a clinical \nevaluation and laboratory tests (biochemical \nand hematological parameters, and urinaly-\nsis). The volunteers were free from signifi-\ncant cardiac, hepatic, renal, pulmonary, neu-\nrological, gastrointestinal and hematological \ndiseases, as assessed by clinical examina-\ntion, ECG and the following laboratory tests: \nblood glucose, urea, creatinine, AST, ALT, \nalkaline phosphatase, ?GT, total bilirrubin \nand fractions, uric acid, total cholesterol, \ntriglycerides, albumin and total protein, he-\nmoglobin, hematocrit, total and differential \nwhite cell counts and routine urinalysis. All \nsubjects were negative for HIV, HBV (except \nfor serological scar) and HCV. The subjects \nwere able to comprehend the full nature and \npurpose of the study, including possible risks \n\nTable 1. Treatment scheme with lodenafil in 1 mg, 2 mg, 3 mg, 5 mg, 8 mg, 10 mg, 20 mg, 30 mg, 50 \nmg, 80 mg and 100 mg in healthy male volunteers.\n\nVolunteer 1 mg 2 mg 3 mg 5 mg 8 mg 10 mg 20 mg 30 mg 50 mg 80 mg 100 mg\nI x x x\nII x x x\nIII x x x\nIV x x x\nV x x x\nVI x x x\nVII x x x\nVIII x x x\nIX x x x\nX x x x\nXI x x x\nXII x x x\nXIII x x x\nXIV x x x\nXV x x x\nXVI x x x\nXVII x x x\nXVIII x x x\nXIX x x x\nXX x x x\nXXI x x x\nXXII x x x\nXXIII x x x\nXXIV x x x\nXXV x x x\nXXVI x x x\nXXVII x x x\nXXVIII x x\nXXIX x x\nXXX x x\nXXXI x\nXXXII x\nXXXIII x\n\n\n\nMendes, Oliveira dos Santos Filho, dos Santos Pereira et al. 898\n\nand side effects and were willing to cooper-\nate with the investigator and comply with the \nrequirements of the entire study. All subjects \nprovided signed consent forms.\n\nThe following exclusion criteria were \nused: laboratory values outside the accepted \nnormal ranges, unless considered not clini-\ncally significant by the investigator; partici-\npation in an experimental study or ingestion \nof an experimental drug 3 months prior to the \ninitiation of the study; any significant clini-\ncal illness or surgery within 8 weeks imme-\ndiately prior to the initiation of the study or \n\nmaintenance therapy with any drug; hospi-\ntalization for any reason within 8 weeks prior \nto the initiation of the study; history of drug, \nmedication or alcohol abuse, or had ingested \nalcohol within 48 hours prior to the begin-\nning of the confinement portion of the study; \nhistory of hepatic, renal, epileptic or hemo-\npoietic disease; hypo- or hypertension of \nany etiology (outside the range of 100 \u2013 140 \nmmHg for systolic and 60 \u2013 90 mmHg for \ndiastolic blood pressure), or heart rate not \nbetween 50 and 90 bpm; myocardial infarc-\ntion, angina pectoris and/or congestive heart \n\nTable 2. Accuracy and precision data for lodenafil carbonate and lodenafil from the pre-study validation \nin human plasma.\n\nLodenafil carbonate\nNominal \n\nconcentration \n(in ng/ml)\n\nIntra-batch \nmean \n\n(in ng/ml)\n\nIntra-batch \nprecision \n(CV %)\n\nIntra-batch \naccuracy \n\n(%)\n\nInter-batch \nmean \n\n(in ng/ml)\n\nInter-batch \nprecision \n(CV%)\n\nInter-batch \naccuracy \n\n(%)\n0.5 0.55 12.55% 109.29% 0.52 15.38% 103.42%\n0.5 0.47 14.16% 93.70%\n0.5 0.53 17.01% 105.89%\n3 3.1 3.61% 102.42% 3.2 8.70% 105.17%\n3 3.1 4.01% 104.50%\n3 3.3 14.98% 109.72%\n\n30 32.8 4.25% 109.25% 33.3 9.32% 110.89%\n30 33.9 10.23% 113.08%\n30 33.1 12.38% 110.33%\n180 187.3 2.33% 104.03% 189.5 6.16% 105.30%\n180 191.4 3.11% 106.32%\n180 190.0 10.30% 105.56%\n\n1,800 1,923 6.06% 106.81% 1894 5.91% 105.23%\n1,800 1,935 5.39% 107.50%\n1,800 1,825 5.03% 101.39%\n\nLodenafil\nNominal \n\nconcentration \n(in ng/ml)\n\nIntra-batch \nmean \n\n(in ng/ml)\n\nIntra-batch \nprecision \n(CV %)\n\nIntra-batch \naccuracy \n\n(%)\n\nInter-batch \nmean \n\n(in ng/ml)\n\nInter-batch \nprecision \n(CV%)\n\nInter-batch \naccuracy \n\n(%)\n0.5 0.54 19.67% 107.13% 0.51 16.39% 101.02%\n0.5 0.48 19.02% 96.37%\n0.5 0.50 7.95% 100.33%\n3 2.8 11.33% 92.29% 2.7 9.66% 90.26%\n3 2.7 7.36% 89.75%\n3 2.7 10.79% 88.52%\n30 28.7 5.25% 95.63% 27.6 8.42% 91.97%\n30 27.8 10.50% 92.75%\n30 25.8 5.18% 86.06%\n180 163.5 5.48% 90.83% 157.7 8.69% 87.59%\n180 157.9 6.61% 87.71%\n180 151.6 12.27% 84.24%\n\n1,800 1,604 3.60% 89.10% 1623 5.32% 90.14%\n1,800 1,685 4.41% 93.61%\n1,800 1,579 5.88% 87.71%\n\nCV = coefficient of variation.\n\n\n\nLodenafil carbonate Phase I study 899\n\nfailure; the subject had donated or lost blood \nwithin 3 months prior to the study or more \nthan 1,500 ml within 12 months preceding \nthe study; any other condition as per inves-\ntigator judgment; high caffeine intake (more \nthan 5 cups of tea or coffee/day); subject who \nsmoked; history or presence of gastrointesti-\nnal, liver or kidney disease or any other con-\ndition known to interfere with the absorp-\ntion, distribution, metabolism or excretion of \ndrugs.\n\nConcomitant medication was to be \navoided where possible during the study. \nAny medication, including over-the-counter \nmedication, was to be recorded.\n\nThe male volunteers had the following \nclinical characteristics (mean \u00b1 SD (range)): \nage 31.1 \u00b1 5.7 y (23 \u2013 40); height 174 \u00b1 6.1 \ncm (160.0 \u2013 184.0); body weight 71.2 \u00b1 9.7 \nkg (54.5 \u2013 90.5). All subjects provided written \ninformed consent, and the Ethics Committee \nof the State University of Campinas approved \nthe protocol. Any major changes required ap-\nproval from the Committee. The study was \nconducted in accordance with Good Clinical \nPractices and provisions of the Declaration of \nHelsinki (1964) and all revisions.\n\nAfter screening and a washout period \n(of at least 2 weeks), the individuals who \nqualified were confined for 3 periods of ~ 40 \n\nTable 3. Mean pharmacokinetic parameters obtained from volunteers after administration of lodenafil carbonate formulation (1 mg, \n2 mg, 3 mg, 5 mg, 8 mg, 10 mg, 20 mg, 30 mg, 50 mg, 80 mg and 100 mg) in 33 healthy volunteers.\n\nDose (mg) 1.00 2.00 3.00 5.00\nVariable Mean SD Mean SD Mean SD Mean SD\nAUC Extrap (%) 65.65 36.92 32.61 23.63 31.39 18.59 30.15 23.04\nAUC? (h\u00d7ng/ml) 15.99 13.19 7.02 3.65 12.82 5.26 12.13 6.02\nAUClast (h\u00d7ng/ml) 2.07 1.98 3.67 2.37 8.11 3.84 6.45 5.89\nCmax (ng/ml) 1.76 1.61 2.87 1.67 2.77 0.42 3.71 2.36\ntmax (h) 0.75 0.00 1.17 0.49 2.06 2.46 2.22 2.06\nKe (1/h) 0.17* 0.20 0.47 0.25 0.30 0.29 0.33 0.20\nt1/2 (h) 14.62* 17.54 2.37 2.38 4.02 2.25 3.33 2.61\nVd (l) 1,009.00* 750.00 925.00 463.00 1,266.00 472.00 1,951.00 1,299.00\nCl (l/h) 95.00* 78.00 355.00 189.00 283.00 147.00 497.00 228.00\n\nDose (mg) 8.00 10.00 20.00 30.00\nVariable Mean SD Mean SD Mean SD Mean SD\nAUC Extrap (%) 31.08 23.41 24.27 24.18 6.75 4.08 14.82 18.71\nAUC? (h\u00d7ng/ml) 22.62 15.73 29.69 24.85 55.53 39.71 86.69 85.97\nAUClast (h\u00d7ng/ml) 17.54 16.34 24.99 24.45 46.18 39.87 82.40 86.41\nCmax (ng/ml) 8.08 6.92 10.92 12.20 19.21 13.74 24.39 19.37\ntmax (h) 2.11 1.29 1.38 0.50 1.86 1.99 1.44 0.92\nKe (1/h) 0.35 0.20 0.41 0.35 0.42 0.30 0.25 0.13\nt1/2 (h) 2.97 2.23 2.66 1.92 2.59 1.75 3.78 2.61\nVd (l) 2,348.00 1,908.00 2,435.00 2,435.00 1,477.00 789.00 6,037.00 7,740.00\nCl (l/h) 613.00 553.00 796.00 821.00 490.00 257.00 1,007.00 1,175.00\n\nDose (mg) 50.00 80.00 100.00 Mean\nVariable Mean SD Mean SD Mean SD Mean SD\nAUC Extrap (%) 5.90 4.83 21.07 29.71 5.23 3.53 \u2013 \u2013\nAUC? (h\u00d7ng/ml) 65.91 51.90 49.16 39.69 89.72 73.32 \u2013 \u2013\nAUClast (h\u00d7ng/ml) 63.37 51.36 42.80 41.95 86.66 73.25 \u2013 \u2013\nCmax (ng/ml) 24.09 15.39 17.62 15.40 37.27 29.02 \u2013 \u2013\ntmax (h) 1.67 1.04 1.86 1.08 1.42 1.02 1.6 0.4\nKe (1/h) 0.32 0.12 0.25 0.16 0.33 0.16 0.3 0.1\nt1/2 (h) 2.59 1.25 5.93 9.12 2.56 1.24 3.3 1.1\nVd (l) 4,137.00 2,902.00 22,971.00 28,532.00 5,581.00 3,189.00 4,913 6,590.5\nCl (l/h) 1,361.00 1,189.00 3,274.00 2,955.00 1,784.00 1,120.00 1,046 914.7\n\nKe = elimination rate constant; t1/2 = half-life; Cmax = maximum plasma concentration; tmax = time to the maximum plasma concentra-\ntion, AUClast = area under curve from time zero to the last detectable concentration AUC? = extrapolation of area to infinity, AUC Ex-\ntrap = % extrapolation of area to infinity; CL = clearance; VD = volume of distribution; Clast = last detectable concentration, tlast = time \nof last detectable concentration, *excluded of descriptive statistic.\n\n\n\nMendes, Oliveira dos Santos Filho, dos Santos Pereira et al. 900\n\nFigure 1. The mean lodenafil plasma concentrations vs. time profiles after a single oral dose (1 mg, 2 mg, \n3 mg, 5 mg, 8 mg, 10 mg, 20 mg, 30 mg, 50 mg, 80 mg, 100 mg) tablet formulation of lodenafil carbonate \nin male volunteers.\n\n\n\nLodenafil carbonate Phase I study 901\n\nhours. Each confinement was intervaled for 1 \nweek. The study was conducted in an open, \nrandomized, dose-escalation, three-period \nopen-label experimental design, involving \nthe administration of increasing single oral \ndoses (1 mg, 2 mg, 3 mg, 5 mg, 8 mg, 10 \nmg, 20 mg, 30 mg, 50 mg, 80 mg, 100 mg) \nof lodenafil carbonate (Table 1). A Fibonac-\nci-like scheme was used for dose escalation \n(from 1 to 10, and from 10 to 100 mg). The \nprogression to the next dose was allowed by \nclinical and laboratory exams, Ambulatory \nMonitoring of Arterial Pressure (AMAP) \nwithout relevant clinical modifications, and \nadverse events without clinical relevancy. \nThe adverse event evaluation was performed \nduring confinement period and in a clinical \nvisit 24 hours before the next confinement. \nThe medical investigator classified the event \nintensity as mild, moderate, severe, and se-\nrious, and the causal relationship to the for-\n\nmulation as unrelated, unlikely, possible and \nprobable.\n\nDuring each period, the volunteers were \nhospitalized between 4:00 p.m. and 7:00 \np.m., having already eaten a normal evening \nmeal. After overnight fasting, they received \nat 7:00 a.m., a single dose of appropriate \nlodenafil carbonate (tablet) along with 240 \nml of tap water. All volunteers were required \nto remain fasting until 2 hours after dose ad-\nministration, when a xanthine-free standard \nbreakfast was available. A xanthine-free \nstandard lunch was provided 5 (lunch), 8 (af-\nternoon snack), 12 (lunch) and 15 (supper) \nhours after dose. A standard meal (lunch) of \nrice, beans, vegetables, and fried chicken, \nplus a fruit as dessert was consumed. The \nbreakfast, afternoon snack and supper in-\ncluded crackers, bread, jelly, cake and apple. \nNo other food was permitted during the \n\u201cin-house\u201d period and liquid consumption \n\nTable 4. Laboratory tests in healthy male volunteers before and after administration of lodenafil carbonate.\n\nType Unit Normal range Pre-study Post-study\nMean SD Min Max Mean SD Min Max\n\nH\nem\n\nat\nol\n\nog\nic\n\nal\n\nHemoglobin g% 13.5 \u2013 17.5 15.4 0.8 14.1 17.2 14.6 0.8 12.9 16.8\nHematocrit % 39 \u2013 50 44.7 1.9 42.2 49.4 42.9 2.1 40.1 47.7\nRed blood count 106/mm3 4.3 \u2013 5.7 5.2 0.6 4.7 8.0 4.8 0.2 4.5 5.2\nVCM Micra3 81 \u2013 95 84.4 17.1 5.2 93.6 89.0 2.4 85.3 93.3\nHbCM Pg 26 \u2013 34 29.6 3.4 14.9 33.4 30.3 1.3 27.4 32.9\nWhite blood count 103/mm3 3,500 \u2013 10,500 6.4 1.3 3.7 8.4 6.9 1.7 4.2 10.6\nBand neutrophils % ? 5 1.7 1.0 1.0 5.0 1.7 0.7 1.0 3.0\nSegmented % 48 \u2013 76 55.0 8.6 36.1 66.7 54.6 8.7 32.1 65.8\nLymphocytes % 25 \u2013 30 31.9 8.6 18.4 50.3 31.8 7.9 21.9 51.5\nMonocytes % 1 \u2013 9 7.7 1.7 4.7 10.3 7.8 2.2 4.8 12.0\nBasophils % 0 \u2013 1 0.6 0.4 0.0 1.8 0.5 0.3 0.0 1.0\nEosinophils % 1 \u2013 5 3.8 2.8 0.6 10.7 4.0 2.5 1.0 9.9\nPlatelet count \u2013 150 \u2013 400 238.5 50.0 153.0 363.0 247.3 44.4 162.0 328.0\n\nB\nio\n\nch\nem\n\nic\nal\n\nTotal cholesterol mg/dl ? 239 167.3 30.9 112.0 239.0 165.5 42.0 22.0 248.0\nTriglycerids mg/dl ? 150 102.4 44.5 45.0 191.0 99.6 54.1 24.0 303.0\nTotal proteins g/dl 6 \u2013  8 7.8 0.3 7.3 8.4 7.7 0.3 7.2 8.3\nAlbumin g/dl 3.5 \u2013  5.5 4.7 0.2 4.4 5.0 4.6 0.2 4.2 5.1\nUric acid mg/dl 2.5 \u2013 7.0 5.5 1.5 3.1 9.0 5.4 1.3 3.0 8.8\nTotal bilirubins mg/dl 0 \u2013  1.1 0.8 0.5 0.4 2.6 0.6 0.4 0.0 1.4\nAlkaline phosphatase U/L 27 \u2013  100 76.2 18.9 49.0 115.0 67.6 24.5 0.8 116.0\ngT U/L  24.1 11.9 8.0 63.0 23.8 11.2 5.2 47.0\nSGOT (AST) U/L ? 43 21.9 5.5 15.0 42.0 20.2 4.1 12.0 34.0\nSGPT (ALT) U/L ? 43 23.2 11.0 13.0 64.0 23.1 9.7 10.0 53.0\nUrea mg/dl 10 \u2013 50 26.6 5.4 14.4 36.7 29.1 5.5 17.2 38.0\nCreatinine mg/dl 0.4 \u2013 1.3 1.1 0.8 0.8 4.7 1.1 0.9 0.7 4.5\nFasting blood glucose mg/dl 60 \u2013 100 87.2 8.1 74.0 108.0 87.9 6.9 74.0 101.0\n\nU\nrin\n\ne\n\nSpecific bravity \u2013 1.015 \u2013 1.028 1019.3 5.8 1,008.0 1,029.0 1,019.6 6.1 1,006.0 1,032.0\npH \u2013 5.5 \u2013 6.5 6.2 0.6 5.5 7.0 6.2 0.4 5.5 6.5\nWBC /ml ? 10,000 7,124.2 16,901.9 300.0 97,000.0 3,277.0 1,924.3 1,000.0 9,400.0\nRBC /ml ? 5,000 4,150.0 4,784.6 300.0 19,430.0 2,900.0 3,924.6 100.0 22,900.0\n\n\n\nMendes, Oliveira dos Santos Filho, dos Santos Pereira et al. 902\n\nwas allowed ad libitum after lunch (with the \nexception of xanthine-containing drinks, in-\ncluding tea, coffee, and cola). No comedica-\ntion was permitted during the study.\n\nBlood samples (5 ml) from a suitable an-\ntecubital vein were collected by an indwell-\ning catheter into heparin containing tubes at \npre-dose, 0.25, 0.5, 0.75, 1, 1.25, 1.5, 1.75, 2, \n2.5, 3, 3.5, 4, 4.5, 5, 6, 7, 8, 10, 12, 14, 16, 20 \nand 24 h post-dosing.\n\nThe Ambulatory Monitoring of Arterial \nPressure (AMAP) was measured for 24 hours \nafter drug administration, with 15-min inter-\nvals in the first 2 hours and then every hour \nuntil the end of the internment (24 hours \nafter the administration of the lodenafil car-\nbonate). Two ECGs were obtained 1 hour \nand 12 hour after the administration of the \nlodenafil carbonate.\n\nFormulations\n\nThe following formulations were em-\nployed: lodenafil carbonate test formulation \ntablet in 1 mg (lot 318/04), 2 mg (lot 319/04), \n3 mg (lot 320/04), 5 mg (lot 321/04), 8 mg \n(lot 378/04), 10 mg (lot 379/04), 20 mg (lot \n392/04), 30 mg (lot 391/04), 50 mg (lot \n394/04), 80 mg (lot 396/04) and 100 mg (lot \n397/04) from Crist\u00e1lia Produtos Qu\u00edmicos e \nFarmac\u00eauticos Ltda, Itapira, Brazil.\n\nChemicals and reagents\n\nLodenafil carbonate (lot number: SL24-\n024), lodenafil (lot number: not available), \nsildenafil (lot number: 20227/99) were pro-\nvided by Crist\u00e1lia Produtos Qu\u00edmicos e \nFarmac\u00eauticos Ltda, Itapira, Brazil. Aceto-\nnitrile, formic acid and methanol were pur-\nchased from J. T. Baker, USA. Diethyl ether \nand hexane were purchased from Mallinck-\nrodt, USA. Blank human blood was collect-\ned from healthy, drug-free volunteers. Plas-\nma was obtained by centrifugation of blood \ntreated with sodium heparin. Pooled plasma \nwas prepared and stored at approximately \n\u201320 \u00b0C until needed.\n\nCalibration standards and quality \ncontrols\n\nStock solutions of lodenafil carbonate, \nlodenafil and the internal standard (silde-\nnafil) were prepared in acetonitrile/water \n(50/50, v/v) at concentrations of 1 mg/ml. \nCalibration curves of lodenafil carbonate \nand lodenafil were prepared by spiking blank \nplasma at concentrations of 0.5, 1.0, 5.0, \n20.0, 50.0, 200, 1,000 and 2,000 ng/ml and \neach concentration was analyzed in dupli-\ncate. The quality control samples were pre-\npared in blank plasma at concentrations of 3, \n30, 180 and 1,800 ng/ml (QCA, QCB, QCC \nand QCD, respectively). The spiked plasma \nsamples (standards and quality controls) \nwere extracted in each analytical batch along \nwith the unknown samples.\n\nDrug analysis\n\nThe blood samples (5 ml) were centri-\nfuged at 2,500 g for 10 min at 4 \u00b0C and the \nplasma decanted and stored at \u201320 \u00b0C until \nassayed for lodenafil carbonate and lodenafil \ncontents. Lodenafil carbonate, lodenafil, and \nthe IS were extracted from plasma samples \nand quantified by liquid chromatography \ntandem mass spectrometry (LC-MS-MS) \nwith positive electrospray ionization using \nmultiple reaction monitoring (MRM).\n\nBriefly, 0.2 ml of each plasma sample \nwas pipetted into a glass tube followed by \n0.05 ml of the internal standard solution \n(1,000 ng/ml of sildenafil (Crist\u00e1lia Produtos \nQu\u00edmicos e Farmac\u00eauticos Ltda, Itapira, Bra-\nzil.) and 4 ml of hexane/diethyl-ether (20/80; \nv/v) (HPLC grade, J. T. Baker, Phillipsburg, \nNJ, USA). The tubes were briefly vortex-\nmixed (40 s). The upper organic layers were \nremoved and transferred into another sterile \ntube, and evaporated to dryness under N2 (at \n40 \u00b0C). The dry residues were dissolved with \n0.2 ml of acetonitrile/water (50/50; v/v) and \nthe solutions were transferred to glass micro-\nvials using automatic pipettes with dispos-\nable plastic tips. The vials were caped and \nplaced into the autosampler (10 \u00b0C) racks.\n\nHigh performance liquid chromatogra-\nphy (HPLC) was performed on C18, 4 \u00b5m \n(100 \u00d7 2.1 mm i.d. (Jones Chromatography, \nGenesis, USA) at a flow rate of 0.45 ml/min \n\n\n\nLodenafil carbonate Phase I study 903\n\nand pressure of the system was ~ 120 bar. \nThe mobile phase was acetonitrile/water \n(90/100; v/v) + 0.1% formic acid (Analysis \nGrade, J. T. Baker, USA). The column oper-\nated at room temperature. The temperature \nof the auto sampler operated at 10\u00b0 \u00b1 2 \u00b0C \nand the injection volume was 10 \u00b5l.\n\nTypical standard retention times were \n1.1 \u00b1 0.2 min for lodenafil carbonate, 0.8 \u00b1 0.1 \nmin for lodenafil and 0.8 \u00b1 0.1 min for the \nIS, and the total run-time was 2.4 min. The \nmass spectrometer (model API 4000, Sciex/\nApplied Biosystems, Foster City, CA, USA) \nequipped with a turbospray source using a \ncrossflow counter electrode, was run in posi-\ntive mode (ES+) with multiple reaction moni-\ntoring (MRM). The mass spectrometer was \nset as follows: 1035.2 > 487.1, 505.2 > 487.0 \nand 475.1 > 283.2, for lodenafil carbonate, \nlodenafil and sildenafil, as the precursor ions \n\nand the respective product ions m/z. The limit \nof quantification in plasma was 0.5 ng/ml for \nboth lodenafil carbonate and lodenafil.\n\nAssay performance\n\nA linear regression with a weighting \nindex of 1/x^2 was performed on the peak \narea ratios of lodenafil carbonate and the \ninternal standard versus the lodenafil car-\nbonate concentrations of eight human plas-\nma standards (in duplicate) to generate a \ncalibration curve. A linear regression with \na weighting index of 1/x^2 was performed \non the peak area ratios of lodenafil and \nthe internal standard versus the lodenafil \nconcentrations of the eight human plasma \nstandards (in duplicate) to generate a cali-\nbration curve.\n\nPrecision and accuracy: Within- and be-\ntween-run precision was determined as the \nrelative standard deviation, RSD (%) = 100 \n(SD/M), and the accuracy as the percentage \nrelative error, RE (%) = (E-T)(100/T), where \nM is the mean, SD is the standard deviation \nof M, E is the experimentally determined \nconcentration and T is the theoretical con-\ncentration.\n\nPharmacokinetics\n\nIndividual plasma level-time curves were \nconstructed and pharmacokinetic parameters \nwere obtained according to a non-compart-\nmental approach. The first-order terminal \nelimination rate constant (ke) was estimated by \nlinear regression from the points describing the \nelimination phase in a log-linear plot, and the \nhalf-life (t1/2) was derived from this rate con-\nstant (t1/2 = ln (2)/ke). The maximum plasma \nconcentration (Cmax) and the time taken to \nachieve this concentration (tmax) were obtained \ndirectly from the curves. The areas under the \nlodenafil plasma concentration vs. time curves \nfrom time zero to the last detectable concentra-\ntion (AUClast) were calculated by applying the \nlinear trapezoid rule. Extrapolation of these ar-\neas to infinity (AUC?) was done by adding the \nvalue Clast/ke to the calculated AUClast (where \nClast = the last detectable concentration). Clear-\nance (CL) was calculated by the formula dose/\nAUC0-?. Volume of distribution (Vd) was cal-\n\nFigure 2. Mean sitting systolic and diastolic blood \npressures and sitting heart rates after lodenafil car-\nbonate administration.\n\n\n\nMendes, Oliveira dos Santos Filho, dos Santos Pereira et al. 904\n\nculated by the formula Dose/Ke(AUC?). The \nsoftware used included WinNonLin Profes-\nsional Network Edition (Scientific Consulting, \nv. 3.0), Microsoft Excel (v. 7.0) and GraphPad \nPrism (v. 3.02).\n\nResults\n\nAll biochemical parameters monitored \npresented no clinically relevant alterations \nduring the Phase I study. No significant \nchanges were observed in the laboratory \nexams and in the ECGs intra-study. Toler-\nance of both formulations (1 \u2013 100 mg) was \ngood and no significant adverse events were \nobserved or reported. One volunteer had an \nadverse event (dysuria not related to therapy \nand classified as not serious) after the dis-\ncharge of the third confinement period dur-\ning the Phase I study. Two volunteers related \nspontaneous erections after administration \nof lodenafil carbonate (30 and 50 mg): one \nduring the clinical evaluation for discharge \n\nof the study and one during the final clinical \nevaluation in the first period of confinement.\n\nLaboratory tests after administration of \nlodenafil carbonate are shown in Table 4. \nBlood pressure and heart rate were assessed \nfor 24 h after treatment with lodenafil car-\nbonate (Figure 2) (Table 5).\n\nThe mean lodenafil plasma concentrations \nvs. time profiles after testing single oral doses \nof lodenafil carbonate in males are shown in \nFigure 1. Calculated mean pharmacokinetic \nparameters of lodenafil are given in Table 3.\n\nThe method was linear for lodenafil car-\nbonate and lodenafil concentrations from 0.5 \nto 2,000 ng/ml. No significant matrix effect \nwas observed. The limit of quantification \n(LOQ), defined as the lowest concentration \nat which both the precision and accuracy \nwere &lt;20%, was 0.5 ng/ml for lodenafil \ncarbonate and lodenafil. The within- and \nbetween-run precision and accuracy for the \nquality controls are summarized in Table 2.\n\nTable 5. Mean sitting systolic and diastolic blood pressures and mean heart rates after lodenafil carbon-\nate administration.\n\nTime Mean diastolic blood \npressures\n\nMean systolic blood \npressures\n\nMean heart rate\n\nMean SD Min Max Mean SD Min Max Mean SD Min Max\n0 71 7 56 89 113 8 91 132 63 7 41 86\n1 70 7 54 93 113 8 86 134 59 7 42 77\n2 72 8 52 96 114 8 88 134 61 8 43 85\n3 69 9 45 99 115 8 88 145 65 10 45 100\n4 68 9 41 93 115 10 95 138 66 10 43 107\n5 71 10 44 97 118 9 89 143 72 11 48 107\n6 65 9 40 89 113 10 77 135 67 8 49 85\n7 66 10 40 96 112 9 85 133 68 10 46 99\n8 67 9 40 93 112 10 90 135 66 10 46 92\n9 65 11 43 86 112 16 90 140 65 12 46 97\n10 66 9 43 88 112 11 84 143 68 10 48 92\n11 68 11 44 90 114 10 86 138 65 10 48 92\n12 74 10 50 98 117 11 94 149 70 14 47 111\n13 70 11 44 95 117 10 93 146 69 11 47 104\n14 69 10 44 89 116 10 82 143 70 10 49 102\n15 64 10 46 94 112 11 91 142 66 10 46 99\n16 65 8 46 84 113 10 83 144 67 11 45 115\n17 62 9 44 80 110 10 84 135 64 10 44 89\n18 63 10 41 89 110 11 86 136 62 11 42 98\n19 63 8 43 81 108 8 87 127 62 13 42 138\n20 65 8 45 88 109 10 88 133 62 10 42 87\n21 62 10 43 91 105 11 83 142 60 10 46 105\n22 62 10 40 84 105 12 79 132 59 9 41 82\n23 63 11 42 91 106 11 74 127 61 11 39 98\n24 73 8 54 91 116 7 98 132 70 9 49 91\n\n\n\nLodenafil carbonate Phase I study 905\n\nDiscussion\n\nHigh-performance liquid chromatography \n(HPLC) coupled with tandem mass spec-\ntrometry (LC-MS-MS) in animal and hu-\nman plasma has been used for lodenafil and/\nor lodenafil carbonate quantification [1, 4]. \nHowever, no full validation method has been \npreviously published for lodenafil and lode-\nnafil carbonate quantification. Our method \nemployed sildenafil as internal standard in-\nstead of theophylline, having a shorter reten-\ntion time of 1.1 min for lodenafil carbonate \nand 0.8 min for lodenafil. The limit of quan-\ntification (0.5 ng/ml) was adequate for phar-\nmacokinetic evaluation of lodenafil carbon-\nate and lodenafil.\n\nThe results obtained following oral ad-\nministration of lodenafil carbonate in healthy \nmale volunteers show that lodenafil carbon-\nate acts as a prodrug when given orally, since \nno quantifiable lodefanil carbonate concen-\ntration has been detected in the systemic \ncirculation. Similar results were observed in \nmale beagles following oral administration \nof lodenafil carbonate [1].\n\nThe adverse event of dysuria was evalu-\nated as not serious since the volunteer spon-\ntaneously recovered and only reported in the \nmedical final evaluation.\n\nAfter the oral administration of the lode-\nnafil carbonate 80 mg tablets to the volun-\nteers, the tmax (1.6 h) and t1/2 (3.3 h) were \nsimilar to the reported in the literature (tmax: \n1.2 \u2013 1.5 h; t1/2: 2.4 \u2013 3 h) [2]. The Cmax \n(17.62 ng/ml) and AUC (42.80 h\u00d7ng/ml) \nvalues were different to those reported in the \nliterature (Cmax 158 ng/ml; AUC 528 h\u00d7ng/\nml) for a lodenafil carbonate tablet (dose 160 \nmg; two tablets of 80 mg) formulation [2].\n\nAs shown in Table 3, the pk parameters \ncalculated for 1 mg are not reliable due to \nlow plasma lodenafil after a dose of 1 mg. \nThe major differences for t1/2, Cl and Vd \nover the dose range can be explained by the \nlow number (n = 3 to 1 mg; n = 6 to 2 mg and \nn = 9 between 3 mg and 100 mg) of volunteer \nper dose and by the variability inter-subject.\n\nThe mean lodenafil pharmacokinetic pa-\nrameters for tmax (1.6 \u00b1 0.4 h) was similar \nto the PDE5 (sildenafil 1 h, tadalafil 1.8 h, \nvardenafil 0.75 h, udenafil 1 h, and avanafil \n0.33 h). The mean lodenafil pharmacokinetic \nparameters for t1/2 (3.3 h) were similar to the \n\nsildenafil and vardenafil (sildenafil 2.76 h, \nvardenafil 2.63 h, avanafil 5.36 h, udenafil \n11 h and tadalafil 21.1 h) [6, 7, 8, 9, 10].\n\nNo serious adverse events were ob-\nserved, and none of the subjects discontin-\nued the study because of lack of tolerance. \nAs shown in Table 4 and Table 5, the AMAP \nmeasurements and clinical tests revealed no \nsignificant alteration even at a higher dose. \nThe lodenafil carbonate presented good tol-\nerance and safety for healthy male volunteers \nin Phase I study. The recommended dose of \n80 mg was used in following trials and it is \nthe commercial formulation dose marketed \nin Brazil.\n\nAcknowledgments\n\nThe Phase I trial was sponsored by Cris-\nt\u00e1lia Produtos Qu\u00edmicos e Farmac\u00eauticos \nLtda, Itapira, Brazil. AcademicEnglishSolu-\ntions.com revised the English. Gilberto De \nNucci is a visiting Professor at the Depart-\nment of Clinical Pharmacy, King Saud Uni-\nversity, Riyadh, Saudi Arabia.\n\nReferences\n[1] Toque HA, Teixeira CE, Lorenzetti R, Okuyama CE, \n\nAntunes E, De Nucci G. Pharmacological charac-\nterization of a novel phosphodiesterase type 5 \n(PDE5) inhibitor lodenafil carbonate on human and \nrabbit corpus cavernosum. Eur J Pharmacol. 2008; \n591: 189-195. doi:10.1016/j.ejphar.2008.06.055 \nPubMed\n\n[2] Silva AC, Toffoletto O, Lucio LA, Santos PF, \nAfiune JB, Massud Filho J, Tufik S. [Cardiovascular \nrepercussion of lodenafil carbonate, a new PDE5 \ninhibitor, with and without alcohol consumption]. \nArq Bras Cardiol. 2010; 94: 150-156, 160-167, \n152-158. PubMed\n\n[3] Glina S, Toscano I, Gomatzky C, de G\u00f3es PM, \nJ\u00fanior AN, Claro JF, Pagani E. Efficacy and \ntolerability of lodenafil carbonate for oral therapy \nin erectile dysfunction: a phase II clinical trial. J \nSex Med. 2009; 6: 553-557. \ndoi:10.1111/j.1743-6109.2008.01079.x PubMed\n\n[4] Glina S, Fonseca GN, Bertero EB, Dami\u00e3o R, \nRocha LC, Jardim CR, Cairoli CE, Teloken C, \nTorres LO, Faria GE, da Silva MB, Pagani E. \nEfficacy and tolerability of lodenafil carbonate for \noral therapy of erectile dysfunction: a phase III \nclinical trial. J Sex Med. 2010; 7: 1928-1936. \ndoi:10.1111/j.1743-6109.2010.01711.x PubMed\n\n[5] Di\u00e1rio Oficial da Uni\u00e3o \u2013 DOU. http://ww w.in.go \nv.br/imprensa/visualiza/index.jsp?jo rna l = 1010&amp; \npagina = 22&amp;data = 22/10/2007.\n\n[6] Stavros F, Kramer WG, Wilkins MR. The effects \nof sitaxentan on sildenafil pharmacokinetics and \n\nhttp://dx.doi.org/10.1016/j.ejphar.2008.06.055\nhttp://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;list_uids=18593576&amp;dopt=Abstract\nhttp://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;list_uids=18593576&amp;dopt=Abstract\nhttp://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;list_uids=20428608&amp;dopt=Abstract\nhttp://dx.doi.org/10.1111/j.1743-6109.2008.01079.x\nhttp://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;list_uids=19040623&amp;dopt=Abstract\nhttp://dx.doi.org/10.1111/j.1743-6109.2010.01711.x\nhttp://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;list_uids=20214718&amp;dopt=Abstract\n\n\nMendes, Oliveira dos Santos Filho, dos Santos Pereira et al. 906\n\npharmacodynamics in healthy subjects. Br J Clin \nPharmacol. 2010; 69: 23-26. \ndoi:10.1111/j.1365-2125.2009.03541.x PubMed\n\n[7] Garraffo R, Lavrut T, Ferrando S, Durant J, \nRouyrre N, MacGregor TR, Sabo JP, Dellamonica \nP. Effect of tipranavir/ritonavir combination on the \npharmacokinetics of tadalafil in healthy volunteers. \nJ Clin Pharmacol. 2011; 51: 1071-1078. \ndoi:10.1177/0091270010379808 PubMed\n\n[8] Berry B, Altman P, Rowe J, Vaisman J. Com pa rison \nof Pharmacokinetics of Vardenafil Administered \nUsing an Ultrasonic Nebulizer for Inhalation vs. a \nSingle 10-mg Oral Tablet. J Sex Med. 2009; Jul \n28. [Epub ahead of print]. \ndoi:10.1111/j.1743-6109.2009.01403.x PubMed\n\n[9] Zhao C, Kim SW, Yang DY, Kim JJ, Park NC, Lee \nSW, Paick JS, Ahn TY, Min KS, Park K, Park JK. \nEfficacy and safety of once-daily dosing of \nudenafil in the treatment of erectile dysfunction: \nresults of a multicenter, randomized, double-\nblind, placebo-controlled trial. Eur Urol. 2011; \n60: 380-387.\n\n[10] Jung J, Choi S, Cho SH, Ghim JL, Hwang A, Kim \nU, Kim BS, Koguchi A, Miyoshi S, Okabe H, Bae \nKS, Lim HS. Tolerability and pharmacokinetics of \navanafil, a phosphodiesterase type 5 inhibitor: a \nsingle- and multiple-dose, double-blind, randomized, \nplacebo-controlled, dose-escalation study in healthy \nKorean male volunteers. Clin Ther. 2010; 32: \n1178-1187. doi:10.1016/j.clinthera.2010.06.011 \nPubMed\n\n[11] Report of the Dietary Guidelines Advisory Com\u00ad\nmittee on the Dietary Guidelines for Americans. \n2000, http://www.health.gov/diet aryguidelines/ \ndgac/pdf/dgac_ful.pdf\n\n[12] Limin M, Johnsen N, Hellstrom WJ. Avanafil, a \nnew rapid-onset phosphodiesterase 5 inhibitor for \nthe treatment of erectile dysfunction. Expert Opin \nInvestig Drugs. 2010; 19: 1427-1437. doi:10.151\n7/13543784.2010.518955 PubMed\n\n[13] De Nucci G. Estudo cl\u00ednico fase I do carbonato de \nlodenafila em volunt\u00e1rios sadios do sexo masculino. \nInt Braz J Urol. 2007; 33 (Suppl 2): 148.\n\nhttp://dx.doi.org/10.1111/j.1365-2125.2009.03541.x\nhttp://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;list_uids=20078609&amp;dopt=Abstract\nhttp://dx.doi.org/10.1177/0091270010379808\nhttp://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;list_uids=21209236&amp;dopt=Abstract\nhttp://dx.doi.org/10.1111/j.1743-6109.2009.01403.x\nhttp://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;list_uids=19656275&amp;dopt=Abstract\nhttp://dx.doi.org/10.1016/j.clinthera.2010.06.011\nhttp://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;list_uids=20637970&amp;dopt=Abstract\nhttp://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;list_uids=20637970&amp;dopt=Abstract\nhttp://dx.doi.org/10.1517/13543784.2010.518955\nhttp://dx.doi.org/10.1517/13543784.2010.518955\nhttp://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;list_uids=20939743&amp;dopt=Abstract\n\n\n \n\n 73  \n \n\nANEXO IV \n\nOutras publica\u00e7\u00f5es durante o per\u00edodo de doutorado \n\n \n\nCurr Drug Metab. 2005 Dec;6(6):519-29. \n\nPharmacokinetics of dihydroergocristine and its major metabolite 8'-hydroxy-\n\ndihydroergocristine in human plasma. \n\nBicalho B, Guzzo GC, Lilla S, Dos Santos HO, Mendes GD, Caliendo G, Perissutti E, Aiello \n\nA, Luciano P, Santagada V, Pereira AS, De Nucci G. \n\nGaleno Research Unit, R. Latino Coelho 1301, Campinas, SP, Brazil. \n\nAbstract \n\nDihydroergocristine (DHEC) is a semi-synthetic drug mainly used for age-related cognitive \n\nimpairment. In this study, its major metabolite 8'-hydroxy-dihydroergocristine (8'-OH-DHEC) \n\nwas produced in incubates of a bovine liver preparation using dihydroergocristine mesylate \n\n(DHECM) as substrate. Purification was achieved by flash silica gel column and reverse \n\nphase liquid chromatographies, and identification was based on accurate molecular mass \n\nmeasurements, mass fragmentation spectra and NMR ((1)H/(13)C) chemical shifts. By using \n\nthe substance produced in vitro, a fast, sensitive, specific and robust LC/MS/MS method for \n\nthe simultaneous determination of DHEC and its major metabolite in human plasma was \n\ndeveloped and validated. Bromocriptine was used as internal standard and limits of \n\nquantification for DHEC and 8'-OH-DHEC were 10 pg/ml and 20 pg/ml, respectively. \n\nPharmacokinetic parameters were investigated on 12 male healthy volunteers to whom a \n\nsingle dose of 18 mg DHECM was administered in tablets (Iskevert). The peak of DHEC was \n\n0.28 +/- 0.22 microg/l, the t(max) 0.46 +/- 0.26 h, the AUC(last) 0.39 +/- 0.41 microg/l.h and \n\nthe terminal elimination half-life 3.50 +/- 2.27 h. The peak of 8'-OH-DHEC was 5.63 +/- 3.34 \n\nadriana.yamaguchi\nTexto digitado\n\n\n\n \n\n 74  \n \n\nmicrog/l, the t(max) 1.04 +/- 0.66 h, the AUC(last) 13.36 +/- 5.82 microg/l.h and the terminal \n\nelimination half-life 3.90 +/- 1.07 h. Dosing of 18 mg DHECM was well tolerated, causing no \n\nadverse events. \n\nPMID: 16379666 \n\n \n\n \n\n \n\n \n\n \n\n \n\n \n\n \n\n \n\n \n\n \n\n \n\n \n\n \n\n \n\n \n\n \n\n\n\n \n\n 75  \n \n\nArzneimittelforschung. 2007;57(9):582-90. \n\nComparative bioavailability study with two amiodarone tablet formulations \n\nadministered with and without food in healthy subjects. \n\ndos Santos Filho HO, Ilha JO, Silva LC, Borges A, Mendes GD, De Nucci G. \n\nCartesius Analytical Unit, Department of Pharmacology, Institute of Biomedical Sciences, \n\nUniversity of S\u00e3o Paulo, S\u00e3o Paulo, SP, Brazil. \n\nAbstract \n\nOBJECTIVE:  The aim was to assess the comparative bioavailability of two formulations \n\n(200 mg tablet) of amiodarone (CAS 19774-82-4) in healthy volunteers of both sexes, with \n\nand without food. \n\nMETHODS:  The study was conducted using an open, randomized, two-period crossover \n\ndesign with a 3-week washout interval, in two groups, with and without food. Plasma samples \n\nwere obtained for up to 240 h post dose. Plasma amiodarone concentrations were analyzed by \n\nliquid chromatography coupled to tandem mass spectrometry (LC-MS-MS) with positive ion \n\nelectrospray ionization using multiple reactions monitoring (MRM). From the amiodarone \n\nplasma concentration vs. time curves, the following pharmacokinetic parameters were \n\nobtained, with and without food: AUC(last), AUC(inf), AUC(0-240h), AUC(0-72h) and \n\nC(max). \n\nRESULTS:  The limit of quantification was 1 ng/mL for plasma amiodarone analysis. The \n\ngeometric mean and 90% confidence interval CI of Test/Reference percent ratios were, \n\nwithout and with food, respectively: 107.61 (92.73-124.89) and 100.6 (94.1-107.5) for \n\nC(max), 107.05 (95.88-119.51) and 100.2 (96.0-104.7) for AUC(last), 107.27 (95.78-120.15) \n\nand 100.8 (97.0-104.8) for AUC(0-72h), 106.76 (95.84-118.94) and 100.2 (96.0-104.7) for \n\nAUC(0-240h) and AUC(inf) 105.15 (94.18-117.41) and 100.7 (96.6-105.0). \n\n\n\n \n\n 76  \n \n\nCONCLUSION: Since the 90% CI for AUC(0-72) and C(max) ratios were within the 80-\n\n125% interval proposed by the US FDA, it was concluded that the amiodarone 200 mg tablet \n\n(test formulation) with and without food was bioequivalent to the reference 200 mg tablet for \n\nboth the rate and extent of absorption. \n\nPMID:17966757"}]}}}